

July 10, 2009 / Vol. 58 / No. 26

Imported Human Rabies – California, 2008

Compared with rabies in developing countries, human rabies is rare in the United States, but animal rabies is common (1,2). In the United States, most human rabies cases are associated with rabid bats, whereas in developing countries, dogs are the most common reservoir and vector species. In March 2008, a case of imported human rabies in a recently arrived, undocumented Mexican immigrant was laboratory confirmed by public health officials in California. The rabies virus isolated from the patient was a previously uncharacterized variant most closely related to viruses found in Mexican free-tailed bats (Tadarida brasiliensis). The molecular and phylogenetic characterizations of this rabies virus variant have been described previously (3). This report summarizes the epidemiologic investigation and the ensuing public health response. A total of 20 persons, mostly household contacts, received postexposure prophylaxis (PEP) because of potential exposure to rabies virus from the patient. The findings underscore the difficulties encountered in the diagnosis and epidemiologic investigations of imported human rabies cases and the importance of a coordinated public health response across multiple international jurisdictions.

Case Report

On March 17, 2008, a male aged 16 years who had recently entered the United States from Oaxaca, Mexico, was brought by his family to an emergency department (ED) in Santa Barbara County, California, with sore throat and a recent history of not eating or drinking. The ED physician obtained a history with assistance from a translator. The patient's vital signs were remarkable for a mild temperature elevation (100.6°F [38.1°C]) and tachycardia (140 beats per minute). He was awake and alert but agitated and crying. His examination was notable for mild abdominal tenderness. Laboratory studies included a complete blood count, electrolytes, liver function tests, and urinalysis. Results were normal except an elevated blood urea nitrogen value of 20 mg/dL (normal range: 7–18 mg/dL). The patient was given intravenous fluids and discharged with the diagnosis of pharyngitis and abdominal pain.

Several hours later, the patient was brought by his family to the same ED with nausea, vomiting, fever, and sore throat. He was mildly febrile (99.1°F [37.3°C]) with tachycardia (164 beats per minute) and was noted to be agitated and uncooperative. He refused to take fluids and was observed to spit frequently. Because of the patient's agitated behavior and his refusal to take oral fluids, the ED physician suggested that psychiatric consultation might be needed. The patient was again given intravenous fluids for dehydration. He was discharged to his aunt's home with the diagnosis of viral pharyngitis, depression, and anorexia.

The next day, on March 18, the patient experienced vomiting and shaking and then collapsed at his aunt's home. When paramedics arrived, the patient was not breathing and was unresponsive. Resuscitation efforts were not successful.

After the patient's death, the possibility of rabies as a cause of his illness was considered by the ED physician because 1) the patient exhibited hydrophobia and aggressive behavior, and 2) the patient had come to the United States from a canine rabies enzootic region in Mexico only the day before his presentation at the ED.

INSIDE

- 716 Clinic-Based Testing for Rectal and Pharyngeal *Neisseria* gonorrhoeae and *Chlamydia trachomatis* Infections by Community-Based Organizations — Five Cities, United States, 2007
- 719 Progress Toward Poliomyelitis Eradication India, January 2007–May 2009

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION

Weekly

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2009;58:[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH Director Tanja Popovic, MD, PhD Chief Science Officer James W. Stephens, PhD Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Katherine L. Daniel, PhD Deputy Director, National Center for Health Marketing

Editorial and Production Staff

Frederic E. Shaw, MD, ID Editor, MMWR Series Christine G. Casey, MD Deputy Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series Teresa F. Rutledge Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge Writers-Editors Martha F. Boyd Lead Visual Information Specialist Malbea A. LaPete Stephen R. Spriggs Visual Information Specialists Kim L. Bright, MBA Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

Public Health Investigation

The Santa Barbara County Public Health Department and health officials in Mexico interviewed family members and friends of the patient regarding potential rabies exposures. Through these interviews, two potential animal bite exposures were identified. Both occurred in Oaxaca, Mexico. In December 2007, the patient was bitten by a dog while tending sheep. In the same month, he was bitten by a fox. Several other persons who were bitten by the fox received rabies PEP, but the patient did not.

Brain tissue obtained from the patient postmortem was sent to the Santa Barbara Public Health Laboratory. On March 21, rabies virus antigen was identified in the brain tissue by the direct fluorescent antibody test. Brain tissue was forwarded to the California Viral and Rickettsial Disease Laboratory (VRDL) and CDC for viral characterization. After antigenic typing and genetic sequencing on March 27, VRDL and CDC identified a rabies virus variant most closely related to viruses found in Mexican free-tailed bats, rather than a canine rabies virus variant (*3*).

On March 21, by request of the California Department of Public Health, CDC's San Diego Quarantine Station assisted in contacting Mexican federal and local public health authorities to notify them of the case and seek further information regarding the patient's exposures in Mexico. In addition, an investigation was begun by the Santa Barbara County Public Health Department in conjunction with the local hospital's infection control staff and the Ventura County Public Health Department. The investigation was complicated by the patient's undocumented status in the United States, his long-distance travel, and linguistic and cultural barriers.

Investigation determined that the patient had departed Oaxaca, Mexico, on March 10 and traveled through Mexico with others by foot and car before making unauthorized entry into the United States on or shortly before March 16. One of his traveling companions was his brother-in-law, who traveled with him from Oaxaca to the United States. After the patient's arrival in the United States on March 16, he remained at a family residence in Santa Barbara County, California, until the onset of his illness the following day.

Mexican health officials interviewed contacts and family members in the patient's home town; none received PEP because the patient was not considered to be infectious before his departure for California. Intensive efforts to locate the brother-in-law and other traveling companions were not successful. Because the patient had remained at one family residence after his arrival in the United States, contact exposures in the United States were limited to household members, ED staff, and health department personnel. **MMWR**

Assessments of potential exposure were made in accordance with Advisory Committee on Immunization Practices recommendations (2). Of 29 possible contacts identified, 20 were deemed to be potentially exposed and received PEP. Sixteen of those 20 were household members. All received PEP because of exposure of mucous membranes or nonintact skin to the patient's saliva as a result of the patient's frequent spitting and excessive salivation while at the family residence. Four persons who received PEP were health-care providers. Two ED physicians reported exposures to the patient's saliva. A microbiologist and veterinarian technician, who were previously vaccinated and assisted with the specimen preparation, received booster doses of rabies vaccine. To date, all known contacts of the patient in the United States have no evidence of rabies.

Reported by: C Fukagawa, F Alvarez, MD, Santa Barbara County Public Health Dept; S Messenger, PhD, D Schnurr, PhD, S Gavali, CA Glaser, DVM, MD, B Sun, DVM, Div of Communicable Disease Control, Center for Infectious Diseases, California Dept of Public Health. M Ocaña, MD, S Waterman, MD, Div of Global Migration and Quarantine, National Center for Preparedness, Detection, and Control of Infectious Diseases; JD Blanton, MPH, CE Rupprecht, VMD, PhD, Div of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.

Editorial Note: The case described in this report is the first case of human rabies imported into the United States that has not been associated with a canine rabies virus variant. The patient described in this report was infected with a variant most closely related to rabies viruses found in Mexican free-tailed bats (3). During 2000–2008, a total of 27 cases of human rabies were reported in the United States (1). Of these, six were imported cases, including the case described in this report. With the exception of the case described in this report, all were associated with either 1) a history of dog exposure in a canine rabies enzootic country, or 2) a canine rabies virus variant that was enzootic in the patient's country of origin. How the patient described in this report was infected with rabies virus remains unclear. Transmission might have occurred either through a bat bite directly or by secondary infection through the bite of a rabid carnivore infected with a bat rabies virus variant (i.e., the dog or fox bites identified in the investigation). Travelers should be aware of the local status and epidemiology of rabies at their destination and how to prevent exposures by avoiding stray animals and wildlife (4). Patients who have potential exposures to rabies virus should seek medical evaluation immediately.

The patient's mode of travel to the United States likely hindered more immediate prevention efforts by local health officials in his home jurisdiction. The undocumented status of the patient might have led to the patient and his family not readily disclosing complete information to health-care providers or officials, thereby delaying consideration of a rabies diagnosis. Nevertheless, a disoriented, salivating, and dehydrated patient who avoids water should prompt a consideration of rabies in the differential diagnosis, irrespective of a documented history of animal exposure. Health-care providers should consider rabies in patients with acute progressive encephalitis. In particular, rabies should be included in the differential diagnosis where a travel history or immigration status has indicated time spent in a canine rabies endemic country.

The investigation described in this report highlights the importance of cooperation between the United States and Mexican public health agencies for the complete investigation of infectious disease cases that cross international borders (5). Sharing information about the rabies death in this Mexican national enabled officials from Mexico and the United States to conduct timely and coordinated disease surveillance, assess prevention efforts, and accurately document consequent mortality.

This case also demonstrates the need for improved international coordination in the control of infectious disease. CDC, the Mexico Secretariat of Health, and state epidemiology officials from both countries have drafted Guidelines for U.S.-Mexico Coordination on Epidemiologic Events of Mutual Interest (6), which addresses the issue of such binational cases and disease outbreaks to ensure systematic communication for public health purposes. The guidelines were drafted because such binational public health situations between the United States and Mexico are relatively frequent, particularly in border regions. The 2005 International Health Regulations (7) encourage such bilateral agreements to address common disease control issues and public health events in border regions and beyond, because most issues, such as this imported rabies case, do not meet the World Health Organization's definition of a public health emergency of international concern (PHEIC).* Pilot implementation of operation protocols for the proposed U.S.-Mexico guidelines is ongoing.

Acknowledgments

This report is based, in part, on contributions by E Ellis, MD, JT Ritter, MD, Marian Medical Center, Santa Barbara; K White, SPHN, Santa Barbara County Public Health Dept; J Grummer, Div of Communicable Disease Control, Center for Infectious Diseases, California Dept of Public Health; OG Castellanos, Oaxaca Dept of Health; FV Pino, DVM, National Zoonosis Program, Mexico Secretariat of Health; A Velasco, PhD, L Orciari, MS, M Niezgoda, MS, Div of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.

^{*} PHEIC must meet two of the following four criteria: 1) seriousness of the public health impact of the event, 2) unusual or unexpected nature of the event, 3) potential for the event to spread internationally, and/or 4) the risk that restrictions to travel or trade might result because of the event.

References

- Blanton JD, Palmer D, Christian KA, Rupprecht CE. Rabies surveillance in the United States during 2007. J Am Vet Med Assoc 2008;233:884–97.
- CDC. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR 2008;57(No. RR-3).
- 3. Velasco-Villa A, Messenger SL, Orciari LA, et al. New rabies virus variant in Mexican immigrant. Emerg Infect Dis 2008;14:1906–8.
- Blanton JD, Rupprecht CE. Travel vaccination for rabies. Expert Rev Vaccines 2008;7:613–20.
- Waterman SH, Escobedo M, Wilson T, Edelson PJ, Bethel J, Fishbein DB. A new paradigm for quarantine and public health activities at land borders: opportunities and challenges. Public Health Rep 2009;124:203–11.
- 6. Core Group on Epidemiologic Surveillance and Information Sharing Health Working Group, US-Mexico Binational Commission. Guidelines for U.S.–Mexico coordination on epidemiologic events of mutual interest. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www2a.cdc.gov/phlp/docs/us_mexico_epi_info_ sharing.pdf.
- World Health Organization. International Health Regulations (2005). 2nd ed. Geneva, Switzerland: World Health Organization; 2008. Available at http://www.who.int/ihr/9789241596664.

Clinic-Based Testing for Rectal and Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis Infections by Community-Based Organizations – Five Cities, United States, 2007

CDC recommends screening of at-risk men who have sex with men (MSM) at least annually for urethral and rectal gonorrhea and chlamydia, and for pharyngeal gonorrhea (1). Although the standard method for diagnosis is culture, nucleic acid amplification (NAA) testing is generally more sensitive and favored by most experts (2). NAA tests have not been cleared by the Food and Drug Administration (FDA) for the diagnosis of extragenital chlamydia or gonorrhea and may not be marketed for that purpose. However, under U.S. law, laboratories may offer NAA testing for diagnosis of extragenital chlamydia or gonorrhea after internal validation of the method by a verification study.* To determine sexually transmitted disease (STD) testing practices among community-based organizations serving MSM, CDC and the San Francisco Department of Public Health gathered data on rectal and pharyngeal gonorrhea and chlamydia testing at screening sites managed by six gay-focused community-based organizations in five U.S. cities during 2007. This report summarizes the results of the study, which found that three organizations collected samples for NAA testing and three for culture. In total, approximately 30,000 tests were performed; 5.4% of rectal gonorrhea, 8.9% of rectal chlamydia, 5.3% of pharyngeal gonorrhea, and 1.6% of pharyngeal chlamydia tests were positive. These results demonstrate that gay-focused community-based organizations can detect large numbers of gonorrhea and chlamydia cases and might reach MSM not being tested elsewhere. Public health officials could consider providing support to certain community-based organizations to facilitate testing and treatment of gonorrhea and chlamydia.

Gay-focused community-based organizations provide medical and social services and are guided and staffed by paid or unpaid community residents with various skill levels, including some who might have medical, nursing, or counseling backgrounds (4). Funding and other resources are provided by private and public sources. Many gay-focused community-based organizations in cities with large MSM, lesbian, and bisexual populations offer alternative venues to traditional public STD clinics and private physicians by providing onsite STD screening and treatment services. Gay-focused communitybased organizations typically do not require health insurance for access, are located in neighborhoods with many MSM, and provide culturally competent services for a historically stigmatized population.

For this survey, gay-focused community-based organizations were defined as nongovernmental organizations that stated in published materials that they principally serve MSM. During April 2008, the 10 U.S. cities with the highest estimated number of gay, lesbian, or bisexual residents were identified (5). Gay-focused community-based organizations in each city that provide rectal and pharyngeal gonorrhea and chlamydia testing to MSM were identified through community leaders and Internet searches. Organizations were excluded if they did not provide rectal or pharyngeal gonorrhea or chlamydia testing services, or were unable to provide data on types of test used, number of tests performed, or percentage of positive tests during 2007.

Among 11 gay-focused community-based organizations identified in the 10 cities, 10 provided rectal or pharyngeal gonorrhea or chlamydia testing services. Among those 10 organizations, data were available from six in five cities, including Howard Brown Health Center (Chicago, Illinois), Callen-Lorde Community Health Center (New York, New York), AIDS Health Foundation (Los Angeles, California),

^{*} Verification studies permit the use of tests for an indication that does not have formal clearance by FDA. Verification studies can be performed at a single laboratory or in collaboration with a second laboratory. The second laboratory might be able to provide a panel of previously tested positive and negative specimens for comparative purposes. A typical verification protocol involves testing of at least 20 positive and 20 negative specimens compared to the reference standard or to results obtained from a second laboratory. The test performance (i.e., sensitivity and specificity) should be equivalent or better than the reference standard or to those obtained by the second laboratory (*3*).

Los Angeles Gay and Lesbian Center (Los Angeles, California), Magnet (San Francisco, California), and Gay City Health Project (Seattle, Washington). Data for 2007 were collected during April–July 2008. Overall, staff from six organizations collected samples for 6,499 rectal gonorrhea tests and 5,258 rectal chlamydia tests; staff from five organizations collected 14,189 samples for pharyngeal gonorrhea tests; and staff from four organizations collected samples for 3,410 pharyngeal chlamydia tests (Table). Medical oversight at each organization assured proper specimen collection, transport, results disclosure, treatment, and partner notification. Organizations that used NAA testing generally had higher rates of positivity than those that used culture. Pharyngeal and rectal test positivity generally was high compared with urethral testing.

Four of the six organizations sent the specimens to public health laboratories for testing; costs for that testing were funded by local public health jurisdictions. The other two organizations used commercial laboratories for testing; costs for that testing were funded by patient insurance or self-pay. All laboratories had completed verification studies demonstrating adequate NAA testing performance in extragenital specimens.

Reported by: JD Klausner, MD, KT Bernstein, PhD, M Pandori, PhD, San Francisco Dept of Public Health; C Hall, MD, S Gibson, T Ryan, MSN, San Francisco AIDS Foundation and Magnet; R Bolan, MD, S Tilekar, MSc, MPH, Los Angeles Gay and Lesbian Center; H Khanlou, MD, AIDS Healthcare Foundation; P Kerndt, MD, S Guerry, MD, C Wigen, MD, E Rudy, PhD, Los Angeles County Dept of Public Health, California. G Mayer, MD, Callen-Lorde Community Health Center, New York, New York. B Gratzer, MPP, Howard Brown Health Center and Univ of Illinois School of Public Health, Chicago. F Swanson, MA, Gay City Health Project, Seattle; M Golden, MD, Public Health Seattle King County and Univ of Washington. C Kent, PhD, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; KA Katz, MD, EIS Officer, CDC.

Editorial Note: In 2007, chlamydia and gonorrhea were the first and second most commonly reported notifiable diseases in the United States, respectively, with 1,108,374 chlamydia cases (370.2 per 100,000 population) and 355,991 gonorrhea cases (118.9 per 100,000 population) (6). Most chlamydia and gonorrhea testing is performed in traditional medical settings and is indicated for screening, diagnosis, or test-of-cure. During 2007, the six gay-focused community-based organizations in this report collected samples for approximately 30,000 rectal and pharyngeal gonorrhea and chlamydia tests from community members attending each facility and detected approximately 1,600 infections. Tests on samples collected by four of the six organizations surveyed were performed by public health laboratories and funded by local health jurisdictions, illustrating the role that partnerships between government and community-based organizations can play in prevention and control of rectal and pharyngeal gonorrhea and chlamydia.

The percentages of positive NAA tests for rectal and pharyngeal gonorrhea and chlamydia were similar to those reported for NAA testing in a previous study from a publicly funded municipal STD clinic (7). As expected, NAA test positivity for rectal gonorrhea and chlamydia infections and pharyngeal gonorrhea was generally higher than culture test positivity (7).

TABLE. Number of tests performed by gay-focused community-based organizations,* by test type, laboratory, and funding source,
to detect rectal and pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections — five U.S. cities, [†] 2007

			Ree	ctal					Phary	ngeal		
	N. gond	orrhoeae in	fections	C. trac	homatis in	ections	N. gond	orrhoeae inf	ections	C. track	homatis info	ections
Tests performed, by organization (city)	No. tests	No. positive	(%)	No. tests	No. positive	(%)	No. tests	No. positive	(%)	No. tests	No. positive	(%)
NAA [§] tests only												
Los Angeles Gay and Lesbian Center (Los Angeles)**	1,845	206	(11.2)	1,841	248	(13.5)	7,214	471	(6.5)	1		
AIDS Healthcare Foundation (Los Angeles)**	670	30	(4.5)	658	66	(10.0)	1,410	60	(4.3)	—		
Magnet (San Francisco)**	2,307	107	(4.6)	2,307	151	(6.5)	3,397	194	(5.7)	3,397	54	(1.6)
Culture only												
Howard Brown Health Center (Chicago) ^{††}	40	3	(7.5)	34	0	(0)	41	0	(0)	13	0	(0)
Callen-Lorde (New York City) ⁺⁺	1,176	5	(0.4)	_			1,456	4	(0.3)	_		
Gay City Health Project (Seattle)**	461	2	(0.4)	418	3	(0.7)	671	30	(4.5)	—		
Total	6,499	353	(5.4)	5,258	468	(8.9)	14,189	759	(5.3)	3,410	54	(1.6)

* Includes nongovernmental organizations providing sexually transmitted diseases clinics and testing, primarily for men who have sex with men, but might include persons identified as lesbian or bisexual.

[†] Chicago, Illinois; Los Angeles, California; New York, New York; San Francisco, California; and Seattle, Washington.

§ Nucleic acid amplification. All NAA tests were APTIMA Combo 2 assays (Gen-Probe, Inc., San Diego, California).

[¶] Did not test for *C. trachomatis*.

** Testing funded by local health jurisdiction and conducted at local public health laboratory.

^{††} Testing funded by insurance or patient out-of-pocket expenses and conducted at commercial laboratory.

Compared with cultures, NAA tests have numerous advantages in detecting gonorrhea and chlamydia. NAA tests might perform better than cultures in nontraditional medical settings, where specimens for culture could be vulnerable to suboptimal handling, compared with more traditional medical clinics. NAA tests are more sensitive than culture for diagnosis of rectal or pharyngeal chlamydia or gonorrhea among MSM, while preserving specificity >99% (7).[†] Furthermore, NAA tests can detect gonorrhea and chlamydia simultaneously with a single test and can detect infection in self-collected specimens, including rectal and pharyngeal specimens (3). NAA test results can be available within 48 hours, whereas most culture results are not available for at least 48 hours. Unlike cultures, NAA tests do not require specialized equipment for specimen collection (e.g., a carbon dioxide-enriched atmosphere for storage and transport for Neisseria gonorrhoea cultures).

CDC recommends at least yearly screening for rectal gonorrhea and chlamydia for MSM who have had receptive anal intercourse during the preceding year and for pharyngeal gonorrhea for MSM who have participated in receptive oral intercourse during the preceding year. CDC recommends screening at 3-6 month intervals for MSM who have multiple or anonymous partners, have sex in conjunction with illicit drug use, use methamphetamine, or have sex partners who participate in those activities (1). CDC does not recommend routine screening for pharyngeal chlamydia (1). Nonurethral gonorrhea and chlamydia frequently are asymptomatic and often can be present in the absence of urethral gonorrhea or chlamydia, reinforcing the need to screen persons at the relevant exposed anatomic sites (4).

Currently, a low percentage of sexually active MSM at risk for STDs are screened at the minimum frequency recommended by CDC, at least for gonorrhea. In a 2003–2005 national study, 36% of MSM reported being tested for gonorrhea at any anatomic site in the previous year (8). Screening for pharyngeal and rectal gonorrhea among MSM is less common than for urethral gonorrhea, impeding efforts to control gonorrhea transmission among MSM (9).

The findings in this report are subject to at least four limitations. First, data on indication for testing (e.g., diagnostic screening or test of cure) were available only from the Gay City Health Project, which tested only asymptomatic persons using culture; all other community-based organizations tested symptomatic and asymptomatic persons, resulting in a higher prevalence than what is found in reports limited to screening in asymptomatic persons. Second, the unknown, underlying prevalence of infections, which might have varied in the populations tested using NAA tests compared with cultures, was not considered. Third, information regarding the sex of persons tested at the community-based organizations and of the sex partners was not available, so that results could not be limited exclusively to MSM. Finally, this study described the use of only one type of NAA test; other NAA tests might perform differently.

Two large commercial laboratory service vendors, Laboratory Corporation of America and Quest Diagnostics, recently have verified and begun offering NAA tests for diagnosis of rectal and pharyngeal gonorrhea and chlamydia. As more laboratories verify NAA tests to detect gonorrhea and chlamydia, community-based organizations increasingly can be effective partners in the STD prevention efforts to control rectal and pharyngeal gonorrhea and chlamydia, and possibly reduce HIV transmission in MSM. More widespread use of NAA tests likely would allow the detection of infections that might be missed by culture, either because of the relatively lower sensitivity of culture or because persons collecting samples might lack the experience necessary to ensure proper collection and handling. Manufacturers of NAA tests can pursue FDA clearance of those tests for the diagnosis of rectal and pharyngeal gonorrhea and chlamydia by gathering and submitting to FDA sufficient data on test performance for those indications. In the interim, CDC and the Association of Public Health Laboratories can help support increases in NAA testing by providing technical assistance and specimens to laboratories for use in verification studies (2).

Rectal and pharyngeal gonorrhea and chlamydia among MSM remain a public health concern. The feasibility and utility of integrating testing for extragenital gonorrhea and chlamydia into existing services at gay-focused community based organizations likely will depend on many factors (e.g., funding availability, staff training, and regional disease burden). Local health jurisdictions might increase chlamydia and gonorrhea testing among MSM by providing financial and technical support to gay-focused community-based organizations and collaborating with them on activities related to the prevention and control of rectal and pharyngeal gonorrhea and chlamydia.

References

- 1. CDC. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006;55(No. RR-11).
- Association of Public Health Laboratories. Laboratory diagnostic testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. Expert Consultation Meeting Summary Report; January 13-15, 2009; Atlanta, GA. Silver Spring, MD: Association of Public Health Laboratories; 2009. Available at http://www.aphl.org/aphlprograms/infectious/std/documents/ ctgclabguidelinesmeetingreport.pdf.
- Renault CA, Hall C, Kent CK and Klausner JD. Use of NAATs for STD diagnosis of GC and chlamydia in non-FDA-cleared anatomic specimens. MLO Med Lab Obs 2006;38:10, 12–6, 21–2.

[†] Studies have shown sensitivity of 63%–100% for NAA tests, depending on the type of test used, anatomic site sampled, and the organism assayed, versus 27%–41% for culture (5).

- 4. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005;41:67–74.
- Gates, GJ. Same-sex couples and the gay, lesbian, bisexual population: new estimates from the American Community Survey. Los Angeles, CA: University of California, The Williams Institute; 2006. Available at http://www.law.ucla.edu/williamsinstitute/publications/samesexcouples andglbpopacs.pdf.
- 6. CDC. Sexually transmitted disease surveillance, 2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2008. Available at http://www.cdc.gov/std/stats07/toc.htm.
- 7. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637–42.
- Tai E, Sanchez T, Lansky A, Mahle K, Heffelfinger J, Workowski K. Selfreported syphilis and gonorrhoea testing among men who have sex with men: national HIV behavioural surveillance system, 2003–5. Sex Transm Infect 2008;84:478–82.
- Mahle KC, Helms DJ, Golden MR, et al. Missed gonorrhea infections by anatomic site among asymptomatic men who have sex with men (MSM) attending U.S. STD clinics, 2002–2006. In: 2008 National STD Prevention Conference, Chicago, March 10–13, 2008; Atlanta, GA: CDC, the American Sexually Transmitted Disease Association, and the American Social Health Association and the National Coalition of STD Directors; 2008.

Progress Toward Poliomyelitis Eradication – India, January 2007–May 2009

India is the most populous of the four remaining countries (including Afghanistan, Nigeria, and Pakistan) where transmission of wild poliovirus (WPV) has never been interrupted. The last cases of WPV type 2 worldwide were reported in October 1999 in India (1). However, transmission of WPV type 1 (WPV1) and WPV type 3 (WPV3) persists in India in the northern states of Uttar Pradesh and Bihar. Transmission of indigenous WPV in all of India's other states was successfully interrupted in 2002, and all WPV cases reported since then in the country have resulted from WPV circulating in Uttar Pradesh and Bihar. This report updates previous reports (1,2) and summarizes India's progress toward polio eradication since January 2007, as of May 29, 2009. In 2005, the government of India introduced the use of monovalent oral polio vaccine type 1 (mOPV1), which has higher efficacy against WPV1 than does trivalent oral polio vaccine (tOPV) (1-3), in supplementary immunization activities.* After a multistate WPV1 outbreak in 2006, preferential use of mOPV1 was accelerated and WPV1 cases decreased from 83[†] in 2007 to 18 during January–May 2009. A resurgence of WPV3 cases in Uttar Pradesh in 2007 led to an outbreak in Bihar. SIAs using monovalent type 3 OPV (mOPV3) were expanded in 2007 (2), and the number of WPV3 cases declined from 794 in 2007 to 41 during January–May 2009. Simultaneously interrupting transmission in high-risk areas of western Uttar Pradesh and Bihar is the key to successful interruption of all WPV transmission in India.

Immunization Activities

The routine vaccination schedule in India includes doses of tOPV at birth, 6 weeks, 10 weeks, 14 weeks, and 16–24 months. Nationally, estimated routine coverage with 3 or more doses of tOPV by age 12 months was 66% in children aged 12–23 months in 2007–2008 (4). Estimated routine coverage was 53% in Bihar and 40% in Uttar Pradesh (5).

The government of India conducted two national SIA rounds each year in 2007, 2008, and 2009, which used tOPV, mOPV1, or mOPV3 in different areas depending on serotype-specific risk assessment. Additional subnational SIAs with tOPV, mOPV1, or mOPV3 were conducted in areas with ongoing transmission and mop-up activities[§] with either mOPV1 or mOPV3 were conducted in areas with newly identified WPV transmission (Figure 1). Surveys conducted to assess coverage at the end of SIA activity during 2008-2009 have shown that 2%-3% of children in Uttar Pradesh and <1% of children in Bihar were missed during SIAs. SIA quality in both areas has improved from earlier periods (2). Similar surveys in the difficult to access Kosi River basin of Bihar have demonstrated that 6%–13% of children have been missed during SIAs (World Health Organization [WHO], unpublished data, 2009).

Acute Flaccid Paralysis (AFP) Surveillance

The polio eradication initiative relies on surveillance for AFP to identify poliomyelitis cases; AFP surveillance is monitored according to WHO targets for case detection and adequate stool specimen collection.[¶] The national nonpolio AFP rate among children aged <15 years was 9.4 per 100,000 in 2007,

^{*} Mass campaigns conducted for a brief period (days to weeks) in which 1 dose of OPV is administered to all children aged <5 years, regardless of vaccination history. Immunization campaigns can be conducted nationally or in portions of the country. The geographic extent of campaigns (national or subnational) is determined by analysis of surveillance data.

[†] Three cases with simultaneous WPV1 and WPV3 infection occurred in 2007. These cases are included in both the WPV1 total and the WPV3 total.

[§] Mop-up rounds are intensive house-to-house SIAs conducted in a limited area (district or subdistrict) with evidence of recent transmission.

⁹ The WHO target for countries at high risk of polio transmission is a nonpolio AFP rate of at least two cases per 100,000 population aged <15 years, with adequate stool specimen collection from ≥80% AFP cases. Adequate specimens, as defined by WHO, are two specimens collected ≥24 hours apart, both specimens collected within 14 days of paralysis onset and shipped on ice or frozen ice packs to a WHO-accredited laboratory, arriving in good condition.




FIGURE 1. Number of supplementary immunization activity (SIA)* rounds, by vaccine used and district — Uttar Pradesh, Bihar, and surrounding areas, India, January 2007–May 2009

* Mass campaign conducted during a brief period (days to weeks) in which 1 dose of oral poliovirus vaccine is administered to all children aged <5 years, regardless of vaccination history. The geographic extent of campaigns (national or subnational) is determined by analysis of surveillance data. † Monovalent oral poliovirus vaccine type 1.

§ Trivalent oral poliovirus vaccine.

[¶] Monovalent oral poliovirus vaccine type 3.

10.2 per 100,000 in 2008, and 6.6 per 100,000 during January–May 2009. In Bihar and Uttar Pradesh, 12.9–28.4 nonpolio AFP cases per 100,000 were identified during this period. Nationally, adequate stool specimens were collected from 84% of AFP cases during 2007–2008, and 86% of AFP cases from January through May 2009.

Stool specimens from AFP cases undergo virologic testing in one of the eight WHO-accredited national Global Polio Laboratory Network laboratories.** The national reference laboratory in Mumbai performs genomic sequence analysis of all WPV isolates.

WPV Epidemiology

A total of 874 WPV cases were reported from 13 states in 2007 and 559 WPV cases were reported in 13 states in 2008 (Figures 2 and 3). During January–May 2009, 59 WPV cases were reported from four states; 279 cases were reported during the same period in 2008. Among cases reported during 2007–2008, 867 (61%) occurred in children aged <24 months and 44 (3%) occurred in children aged >5 years. Among cases reported during 2007–2008, 1,108 (77%) of the children received >7 doses of OPV, 265 (18%) received 4–7 doses, 40 (3%) received 1–3 doses, and 20 (1%) received zero doses or the number of doses received was unknown.

^{**} These laboratories processed 80,614 specimens in 2007 and 91,222 specimens in 2008 (2). After implementation of a new laboratory algorithm in mid-2007 (6), >80% of intratypic differentiation (i.e., wild or vaccine-related) results are available <21 days after specimen receipt in the laboratory, compared with only 17% in 2006. The mean interval between AFP paralysis onset to confirmation decreased from 58 days in the first quarter of 2007 to 22 days during the second half of 2008.




FIGURE 2. Wild poliovirus (WPV) cases, by type — India, January–December 2007, January–December 2008, and January–May 2009*

* As of May 29, 2009

WPV1. A total of 83 WPV1 cases were reported in 45 districts in 2007, including 46 (55%) cases in Bihar and 22 (27%) in Uttar Pradesh. In 2008, 75 WPV1 cases were reported in 22 districts; among those cases, three (4%) were identified in two districts in Bihar and 62 (83%) were identified in 13 districts in an outbreak in Uttar Pradesh (which included 50 cases in five districts within western Uttar Pradesh). During January–May 2009, India reported 18 WPV1 cases in 11 districts; six cases (33%) were reported from two districts in Bihar and eight (44%) from seven districts in Uttar Pradesh.

The current outbreak in Uttar Pradesh, totaling 70 cases to date, began when a WPV1 case genetically linked to WPV circulating in Bihar was detected in western Uttar Pradesh in May 2008. Until then, no WPV1 cases had been reported in Uttar Pradesh since November 2007, and in the previously highest-risk districts of western Uttar Pradesh since September 2006. All 70 WPV1 cases in Uttar Pradesh are linked genetically to this introduction, and in November 2008; a case genetically linked to this outbreak was conversely detected in Bihar. Among the nine WPV1 cases in Bihar in 2008–2009 to date, at least two genetically distinct chains of transmission were identified, primarily localized in difficult-to-reach populations in the flood-prone areas of the Kosi River basin.

WPV3. In all of India, 794 WPV3 cases were reported in 78 districts in 2007 and 484 cases were reported in 85 districts in 2008; 779 (98%) and 473 (98%) of cases in 2007 and 2008, respectively, occurred in Bihar and Uttar Pradesh. During January–May 2009, 41 WPV3 cases were reported,




FIGURE 3. Number of wild poliovirus (WPV) cases, by type, month, and year of onset and type of supplementary immunization activity* — India, January 2002–May 2009[†]

* Mass campaign conducted during a brief period (days to weeks) in which 1 dose of oral polio vaccine is administered to all children aged <5 years, regardless of vaccination history. The geographic extent of campaigns (national or subnational) is determined by analysis of surveillance data.
 † As of May 29, 2009. WPV cases totaled 1,600 in 2002, 225 in 2003, 134 in 2004, 66 in 2005, 676 in 2006, 874 in 2007, 559 in 2008, and 59 to date in 2009.

versus 274 WPV3 cases reported during the same period in 2008. All 41 cases reported in 2009 have been in Bihar and Uttar Pradesh.

Reported by: Ministry of Health and Family Welfare, Government of India; National Polio Surveillance Project, WHO, New Delhi; Immunization and Vaccine Development Dept, WHO Regional Office for South-East Asia, New Delhi; UNICEF, New Delhi; Poliovirus Laboratory Network, Ahmedabad, Bangalore, Chennai, Coonoor, Kasauli, Kolkata, Lucknow, and Mumbai, India. Polio Eradication Dept, WHO, Geneva, Switzerland. Div of Viral Diseases and Global Immunization Div, National Center for Immunization and Respiratory Diseases; SE Kidd, MD, EIS Officer, CDC.

Editorial Note: Overall, WPV1 incidence in India declined during 2007–2009 following implementation of the recommendations of the Global Advisory Committee on Polio Eradication and the India Expert Advisory Group for Polio Eradication to prioritize the elimination of WPV1; this involved conducting SIA rounds using mOPV1 as often as every 6–8 weeks in high-risk areas. In contrast to other polioendemic countries, WPV transmission in the northern Indian states of western Uttar Pradesh and Bihar persists despite \geq 95% of WPV cases reporting receipt of at least four OPV doses. Persistent transmission in these areas despite high vaccination coverage has been attributed to relatively lower vaccine effectiveness of OPV in northern India than in other populations, possibly resulting from a combination of a high incidence of diarrheal diseases, malnutrition, and a high force of WPV infection^{††} resulting from crowding (*1*,*7*,*8*). Among WPV case children, a very high proportion are vaccinated rather than unvaccinated, which reflects the frequency and high coverage of polio vaccination campaigns.

The interruption of WPV1 transmission in Uttar Pradesh during 2007-2008 indicates that frequent mOPV1 rounds of consistently high coverage with enhanced technical support can be successful, even in areas with the most persistent transmission. Western Uttar Pradesh districts have high population density, poor sanitation, and low socioeconomic status and have been the main reservoir for WPV1 transmission in India in previous years. The 2008–2009 Uttar Pradesh outbreak, caused by WPV1 introduced from Bihar, appears to be diminishing, although the risk for continued transmission or reintroduction persists. In Bihar, the intense focus on vaccinating populations in the Kosi River area has resulted in only three WPV1 cases being reported in 2008 and six cases through May 2009, despite severe floods in Bihar in 2008; these floods displaced high-risk populations, worsened sanitary conditions, and interfered with scheduled SIAs. Genetic data from WPV

^{††} Force of infection is the rate at which susceptible persons acquire infection, often varying by age.

isolated from cases indicate that low-grade WPV1 transmission has continued during 2008–2009 in Bihar in districts of the Kosi River basin. This transmission, often undetected for several months, has resulted occasionally in WPV1 cases in several other states.

The number of reported WPV3 cases in India has declined steadily since the peak of the 2007 outbreak. Most WPV3 cases in 2008 occurred in districts in Uttar Pradesh and Bihar in which less than three SIA rounds of mOPV3 had been administered during 2007. The mOPV3 rounds conducted at the end of 2007 and during 2008 appear to have substantially reduced WPV3 transmission and limited transmission to Bihar and Uttar Pradesh in 2009. Although multiple importations of WPV1 and WPV3 were detected in areas outside Uttar Pradesh and Bihar during 2007–2008, no outbreaks of polio occurred in those other areas, in which prompt and large scale mop-up vaccination rounds, higher vaccine effectiveness, higher routine vaccination coverage, and continued national SIAs have produced higher levels of immunity and lower risk for transmission.

India plans to conduct additional mOPV3 SIA rounds as needed to prevent further WPV3 outbreaks while continuing to use mOPV1 for most SIAs. Based on preliminary data from a clinical trial, the Advisory Committee on Polio Eradication and the India Expert Advisory Group for Polio Eradication have recommended the use of bivalent type 1 and type 3 OPV to substitute for mOPV3 in future SIAs when available. The recently developed bivalent formulation is anticipated to be licensed for use in India later in 2009.

Reaching the goal of polio eradication in India is dependent on ongoing efforts to interrupt remaining WPV transmission simultaneously in high-risk areas of western Uttar Pradesh and Bihar, first WPV1, then WPV3. Strategies to accomplish that include reaching all children during SIAs in the Kosi River area and improving the effectiveness of polio vaccines. Potential interventions to improve the effectiveness of poliovirus vaccines under investigation include the use of inactivated poliovirus vaccine as a supplement to OPV, high-titer mOPV1, and zinc supplementation (9). Surveillance also has been expanded in high-risk areas to examine the potential contribution of older age groups to poliovirus transmission to inform a possible expansion of the target age group in these areas. Continued vigilance, sustained commitment, ongoing research and aggressive responses to new cases will be required to interrupt remaining WPV1 transmission and to eliminate polio in India. Polio eradication activities in India have provided successful operational models for elimination of WPV circulation in India would further serve as a stimulus for the remaining countries with WPV transmission, and ultimately lead to global eradication.

References

- CDC. Progress toward interruption of wild poliovirus transmission worldwide, 2008. MMWR 2009;58:308–12.
- CDC. Progress toward poliomyelitis eradication—India, January 2006–September 2007. MMWR 2007;56:1187–91.
- Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007;369:1356–62.
- Government of India Ministry of Health and Family Welfare. District level household and facility survey (DLHS-3)—2007–2008 (provisional). Available at http://nrhm-mis.nic.in/ui/reports/dlhsiii/india%20fact%20 sheet%20jun_final1.pdf.
- 5. Government of India Ministry of Health and Family Welfare. District level household and facility survey (DLHS-3)—2007–2008. Available at http://www.rchiips.org/state-fact-sheet-rch3.html.
- CDC. Laboratory surveillance for wild and vaccine-derived polioviruses worldwide, January 2007–June 2008. MMWR 2008;57:967–70.
- Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science 2006;314:1150–3.
- Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007;369:1356–62.
- Zinc Investigators Collaborative Group. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. J Pediatr 1999;135:689–97.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending July 4, 2009 (26th week)*


		•	5-year			ases re evious	eported vears	I	0
Disease	Current week	Cum 2009	weekly average [†]	2008	2007	2006	2005	2004	States reporting cases during current week (No.)
Anthrax	_			_	1	1	_	_	
Botulism:									
foodborne	—	9	0	17	32	20	19	16	
infant		26	2	109	85	97	85	87	
other (wound and unspecified)	1	13	1	19	27	48	31	30	CA (1)
Brucellosis	_	43	2	80	131	121	120	114	
Chancroid Cholera	1	19	1	25	23	33	17	30	WA (1)
Cyclosporiasis [§]		2	0	120	7	127	8 542	6	EL (2)
Diphtheria	2	44	12	139	93	137	543	160	FL (2)
Domestic arboviral diseases ^{§,¶} :	_	_	_	_	_	_	_	_	
California serogroup	_	_	3	62	55	67	80	112	
eastern equine	_	_	0	4	4	8	21	6	
Powassan	_	_	Ō	2	7	1	1	1	
St. Louis	_	_	0	13	9	10	13	12	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis [§] ,**:									
Ehrlichia chaffeensis	23	174	24	1,137	828	578	506	338	NY (2), MD (2), VA (2), NC (3), FL (1), KY (1), TN (2), AL (1), AR (1), OK (8)
Ehrlichia ewingii	_	_	0	9	_	_	_		
Anaplasma phagocytophilum	6	106	28	1,026	834	646	786	537	NY (5), OK (1)
undetermined	—	32	11	180	337	231	112	59	
Haemophilus influenzae, ^{††}									
invasive disease (age <5 yrs):		10	0	00	00	00	0	10	
serotype b nonserotype b	2	13 102	0 3	30 244	22 199	29 175	9 135	19 135	GA (1), FL (1)
unknown serotype	7	112	3	163	180	179	217	177	PA (2), OH (2), MD (1), FL (1), OK (1)
Hansen disease§	1	32	2	80	101	66	87	105	OH (1)
Hantavirus pulmonary syndrome [§]	_	4	1	18	32	40	26	24	
Hemolytic uremic syndrome, postdiarrheal§	5	73	7	330	292	288	221	200	OH (4), OK (1)
Hepatitis C viral, acute	15	433	15	878	845	766	652	720	NY (2), OH (4), IA (3), WV (1), NC (1), GA (1),
HIV infection, pediatric (age <13 years)§§	_	_	3	_		_	380	436	FL (1), CO (1), CA (1)
nfluenza-associated pediatric mortality [§] , ^{¶¶}	5	90	1	85	77	43	45	_	NY (1), NYC (2), NJ (1), AZ (1)
_isteriosis	12	249	17	759	808	884	896	753	NY (4), OH (1), FL (1), CO (1), WA (3), CA (2)
Measles***	—	34	4	140	43	55	66	37	
Meningococcal disease, invasive ^{†††} :									
A, C, Y, and W-135	2	147	5	330	325	318	297	—	NC (1), CO (1)
serogroup B	_	79	4	188	167	193	156	—	
other serogroup	_	13	1	38	35	32	27	—	
unknown serogroup	5	239	11	616	550	651	765		GA (1), CA (4)
Numps	3	173	21	454	800	,	314 N	258	NY (1), CA (2)
Novel influenza A virus infections ^{§§§} Plague	_	33,902	0	2 1	4 7	N 17	8	N 3	
Poliomyelitis, paralytic	_				_		1		
Polio virus infection, nonparalytic [§]	_	_	_	_	_	N	N	N	
Psittacosis [§]	_	6	0	8	12	21	16	12	
Q fever total ^{§,1111} :	2	38	4	124	171	169	136	70	
acute	2	34	2	110	_	_	_	_	OH (1), NE (1)
chronic	_	4	0	14	_	_	_	_	
Rabies, human	_	_	0	1	1	3	2	7	
Rubella****	—	1	0	16	12	11	11	10	
Rubella, congenital syndrome	_	1	—	_	_	1	1	_	
SARS-CoV ^{§,††††}	—	_	—	_	—	_	_	—	
Smallpox§	_			_	_	_	_		
Streptococcal toxic-shock syndrome§	1	82	2	157	132	125	129	132	WV (1)
Syphilis, congenital (age <1 yr)	_	81	8	420	430	349	329	353	
Tetanus	_	5	1	19	28	41	27	34	CA(1)
Foxic-shock syndrome (staphylococcal)§	1	40	2	71	92	101	90	95	CA (1)
Γrichinellosis Γularemia	_	10 19	1 5	39 123	5 137	15 95	16 154	5 134	
Typhoid fever	3	162	5 7	447	137 434	95 353	154 324	322	PA (1), NC (1), AZ (1)
Vancomycin-intermediate Staphylococcus aureus		29	0	63	434	353	324	322	(1), NO(1), AZ(1)
ancomycin-resistant Staphylococcus aureus	_	29			2	1	3	1	
Vibriosis (noncholera Vibrio species infections)§	5	124	6	492	549	N	N	N	MN (1), GA (1), FL (2), AZ (1)
(ellow fever	_		U U	102	5.0				

See Table I footnotes on next page.

TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending July 4, 2009 (26th week)*

- -: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts.
- * Incidence data for reporting year 2008 and 2009 are provisional, whereas data for 2004, 2005, 2006, and 2007 are finalized.
- [†] Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 [§] Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and the state of the domestic arboviral diseases and the state of the domestic arboviral diseases.
- influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- ⁺⁺ Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
- ^{§§} Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- 11 Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Eighty-nine influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
- *** No measles cases were reported for the current week.
- ⁺⁺⁺ Data for meningococcal disease (all serogroups) are available in Table II.
- SSS These cases were obtained from state and territorial health departments in response to the pandemic influenza A (H1N1) virus infections and include both confirmed and probable cases in addition to those reported to the National Notifiable Diseases Surveillance System (NNDSS). Because of the volume of cases and the method by which they are being collected, a 5-year weekly average for this disease is not calculated.
- In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- **** No rubella cases were reported for the current week.
- titt Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals July 4, 2009, with historical data



* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and	122 Cities Mortality Data Team
Patsy A. H	Hall
Deborah A. Adams Willie J. Anderson	Rosaline Dhara Michael S. Wodajo
Lenee Blanton	Pearl C. Sharp

(26th week)*			Chlamydi	ia†			Cocc	idiodomy	cosis			Crvr	otosporidi	osis	
		Prev					Prev					Prev		0010	
	Current			Cum	Cum	Current	52 w		Cum	Cum	Current	52 w		Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States New England	10,176 494	22,758 761	25,700 1,655	537,944 19,618	584,378 17,810	80	140 0	465 1	4,403 1	3,352 1	46 3	109 5	482 23	2,263 116	2,137 164
Connecticut	206	232	1,306	5,874	4,981	Ν	Ŭ O	Ó	N N	Ň	_	0	16	16	41
Maine [§] Massachusetts	263	48 323	72 947	1,224 9,659	1,242 8,562	N N	0	0 0	N	N N	_	0 2	6 13	13 35	12 48
New Hampshire Rhode Island [§]	1	32 55	63 244	659 1.617	1,008 1,445	_	0 0	1 0	1	1	2	1 0	4 3	18 4	35 4
Vermont§	24	21	53	585	572	Ν	0	0	Ν	Ν	1	1	7	30	24
Mid. Atlantic New Jersey	1,454	2,852 422	6,734 879	75,543 10,184	74,414 11,382	N	0 0	0 0	N	N	7	13 0	35 4	262 1	256 17
New York (Úpstate)	544	566	4,563	14,659	13,396	N N	Ö O	0	N N	N N	2	4	17	65	73
New York City Pennsylvania	508 402	1,111 808	3,130 1,072	29,754 20,946	28,774 20,862	N	0	0	N	N	5	7	8 15	29 167	48 118
E.N. Central Illinois	360	3,439 1,104	4,382 1,356	78,504 24,317	96,814 28,982	N	0 0	3 0	17 N	28 N	7	24 2	126 13	524 38	531 51
Indiana	260	405	713	11,224	10,818	Ν	0	0	N	N	_	3	17	84	69
Michigan Ohio	16	833 761	1,321 1,300	21,906 12,918	23,207 22,964	_	0 0	3 2	7 10	21 7	6	5 8	13 59	101 178	101 113
Wisconsin	84	387	494	8,139	10,843	Ν	0 0	0	N	N	1	8	46	123	197
W.N. Central Iowa	586 137	1,325 192	1,547 257	31,822 4,814	33,106 4,312	N	Ō	1 0	2 N	N	7 1	17 4	68 30	338 77	310 73
Kansas Minnesota	77 2	178 267	401 330	4,278 5,649	4,505 7,248	N	0 0	0 0	<u>N</u>	<u>N</u>	1	1 4	8 14	38 80	25 76
Missouri Nebraska [§]	304 27	497 97	583 219	12,864 2,249	12,140 2,626	N	0 0	1 0	2 N	N	4	3 2	13 8	53 34	70 43
North Dakota	_	26	60	471	895	N	0	Ō	Ν	Ν	_	0	10	6	1
South Dakota S. Atlantic	39 1,923	58 4,386	85 5,730	1,497 92,492	1,380 115,456	N	0 0	0 1	N 5	N 2	1 4	2 21	9 49	50 425	22 368
Delaware District of Columbia	109	74 129	180 227	2,417 3,479	1,855 3,440	_	Ŭ O	1 0	1	_		0	1	1	7 7
Florida	427	1,386	1,597	34,836	36,007	Ν	0	0	Ν	Ν	3	8	35	135	155
Georgia Maryland [§]	234	740 435	1,909 772	12,221 10,478	20,141 11,506		0 0	0 1	N 4	N 2	1	6 1	20 5	175 19	107 14
North Carolina South Carolina [§]	576	388 534	1,457 1,455	11.776	12,615 13,170	N N	0	0 0	N N	N N	_	1	16 6	47 20	11 22
Virginia [§] West Virginia	446 15	614 69	903 101	15,441 1,844	15,132 1,590	N N	0 0	0	N	N N	_	1 0	4 3	23 5	34 11
E.S. Central	1,275	1,672	2,165	42,551	40,982		0	0			1	3	9	66	56
Alabama [§] Kentucky	451	464 243	600 458	9,862 5,677	12,627 5,506	N N	0 0	0 0	N N	N N	1	1	6 4	19 18	20 12
Mississippi Tennessee§	313 511	440 565	841 796	12,056 14,956	9,418 13,431	N N	0	0	N N	N N	_	0	2	4 25	6 18
W.S. Central	2,106	2,914	4,999	77,191	74,805		0	1		2	_	8	271	25 75	99
Arkansas [§] Louisiana	272 117	278 439	418 1,134	7,304 12,422	7,089 10,572	N	0	0 1	N	N 2	_	1	10 5	15 10	16 21
Oklahoma	549	181	2,732	6,009	6,506	N	0	0	N	N	—	2	16	36	20
Texas [§] Mountain	1,168 295	1,963 1,314	2,526 2,145	51,456 29,458	50,638 36,775	N 48	0 94	0 360	N 3,170	N 2,239	4	3 9	258 38	14 172	42 178
Arizona Colorado	37	414 354	627 1,021	6,895 8,924	12,186 8,974	48 N	91 0	358 0	3,130 N	2,176 N	3	1 2	10 12	16 55	22 36
Idaho§	_	68	314	1,766	1,897	Ν	0	0	Ν	N	1	1	5	24	31
Montana [§] Nevada [§]	151	58 174	88 365	1,472 4,756	1,521 4,992		0 1	0 3	N 33	N 32	_	0 0	4 4	14 7	24 6
New Mexico§ Utah	67	159 85	540 251	3,362 1,250	3,551 2,936	_	0 0	2	2 5	20 9	_	2 0	23 6	39 4	34 15
Wyoming§	40	32	97	1,033	718	—	0	1	—	2	_	0	2	13	10
Pacific Alaska	1,683	3,619 90	4,615 199	90,765 2,138	94,216 2,334	32 N	39 0	172 0	1,208 N	1,080 N	13	11 0	20 1	285 2	175 1
California Hawaii	1,288	2,866 114	3,591 247	72,118 2,805	73,127 2,922	32 N	39 0	172 0	1,208 N	1,080 N	11	6 0	14 1	160 1	96 1
Oregon§	187	198	631	4,792	5,082	N	0	0	Ν	N		2	8	86	39
Washington American Samoa	208	393 0	557 3	8,912	10,751 70	N N	0 0	0 0	N N	N N	2 N	2 0	7 0	36 N	38 N
C.N.M.I. Guam	—	2		_	102		0	0	_	_				_	_
Puerto Rico	334	126	269	3,812	3,597	N	0	0	N	N	N	0	0	N	N
U.S. Virgin Islands		8	17	173	354		0	0			_	0	0		

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardiasi	s				Gonorrhe	a		114		s influenz s, all sero		ve
			vious					vious veeks					/ious		
Reporting area	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	veeks Max	Cum 2009	Cum 2008
United States	189	320	641	7,060	7,525	2,584	5,659	7,164	126,996	163,474	22	50	124	1,389	1,589
New England	1 1	26 6	64 14	471 113	644 153	59 47	97 49	301 275	2,415 1,126	2,485 1,089	_	3 0	16	85 29	87 18
Connecticut Maine [§]	_	4	12	89	60	—	49	275	70	47	_	0	12 2	12	8
Massachusetts New Hampshire	_	10 2	27 10	150 42	274 57	12	37 1	112 6	984 53	1,097 63	_	1 0	5 2	32 6	45 6
Rhode Island§	_	1	8	23	40	—	5	16	159	170	—	0	7	3	4
Vermont [§] Mid. Atlantic		3	15	54	60 1 460		1	4	23	19		0	1	3	6
New Jersey	40	59 7	116 21	1,293 85	1,469 235	277	592 92	1,138 127	14,690 2,056	16,182 2,643	5	11 1	25 7	296 31	292 47
New York (Upstate) New York City	33 2	24 15	81 30	555 334	482 413	100 92	111 210	664 577	2,576 5,516	3,013 4,975	1 2	2 2	20 11	71 73	84 50
Pennsylvania	5	16	46	319	339	85	185	267	4,542	5,551	2	4	10	121	111
E.N. Central	17	45	90	988	1,162	111	1,115	1,627	24,254	34,313	4	7	27	177	257
Illinois Indiana	N	9 0	32 11	171 N	315 N	1 77	360 153	499 256	7,332 3,683	9,880 4,366	_	2 1	9 22	63 36	78 45
Michigan Ohio	 15	12 16	22 31	263 377	256 381	8	294 245	493 482	7,193 3,962	8,513 8,363	4	0 1	3 6	12 57	15 80
Wisconsin	2	9	19	177	210	25	101	149	2,084	3,191	-	0	4	9	39
W.N. Central	12	25	143	627	728	129	295	393	6,847	8,307	_	3	15	79	115
lowa Kansas	5 1	6 3	18 11	134 57	132 56	19 26	32 39	53 83	811 1,026	761 1,091	_	0 0	0 2	11	2 14
Minnesota Missouri	_	0 7	106 22	137 183	191 204	78	46 140	78 184	923 3,232	1,611 3,974	_	0	10 4	18 31	27 49
Nebraska§	6	3	10	74	97	4	25	51	640	689	_	Ó	2	14	15
North Dakota South Dakota	_	0 2	16 11	8 34	10 38	2	2 8	7 20	26 189	56 125	_	0 0	4 0	5	8
S. Atlantic	54	66	108	1,696	1,253	563	1,292	2,142	25,990	39,750	8	14	28	408	399
Delaware District of Columbia	_	0	3 5	14	20 27	25 35	16 51	35 89	434 1,403	575 1,244	_	0 0	2 2	3	4 3
Florida	40	31	57	843	560	153	416	507	10,059	12,122	3	5	10	144	97
Georgia Maryland§	6 4	14 5	67 10	490 109	284 115	 55	266 119	876 212	4,067 2,740	7,297 3,039	3 1	2 1	9 6	81 51	84 65
North Carolina South Carolina§	Ν	0 2	0 8	N 43	N 59	163	141 169	647 421	3,636	5,527 4,802	1	1	17 5	48 28	40 36
Virginia§	4	2 8	31	177	155	131	155	308	3,390	4,767	_	1	6	35	56
West Virginia	_	1	5	20	33	1	11	26	261	377	_	0	3	18	14
E.S. Central Alabama [§]	2 1	8 4	22 12	156 69	202 112	379	515 151	771 216	12,270 2,794	14,807 4,997	_	3 0	6 4	85 23	88 14
Kentucky	N N	0 0	0 0	N N	N N	119 121	80 143	153 253	1,655 3,733	2,135 3,478	—	0	4	14	6 11
Mississippi Tennessee§	1	4	13	87	90	139	143	253 301	4,088	3,478 4,197	_	2	5	48	57
W.S. Central	7	8	22	169	149	794	924	1,294	22,444	25,644	3	2	22	67	75
Arkansas [§] Louisiana	_2	2 2	8 10	56 55	56 56	83 39	86 165	134 420	2,204 4,019	2,264 4,736	1 1	0	2 1	12 11	7 8
Oklahoma Texas [§]	5 N	3 0	18 0	58 N	37 N	381 291	69 568	610 725	2,314 13,907	2,410 16,234	1	1 0	20 1	44	54 6
Mountain	18	27	62	521	592	48	182	333	3.755	6.033	2	4	11	132	188
Arizona	1	3	10	90	53	2	51	82	814	1,779	2	1	7	51	78
Colorado Idaho [§]	9 4	9 3	27 14	180 56	217 68	_	59 3	252 13	1,425 46	1,857 82	_	0	5 2	41 2	35 8
Montana [§] Nevada [§]	4	2 2	9 8	40 41	32 54	 18	2 32	6 86	40 847	56 1,232	_	0 0	1 2	1 10	2 11
New Mexico§	-	2	8	38	43	28	22	52	480	704	_	1	3	15	28
Utah Wyoming [§]	_	7 1	18 4	56 20	107 18	_	5 2	15 8	66 37	275 48	_	0	2 2	12	26
Pacific	38	54	130	1,139	1,326	224	559	755	14,331	15,953	_	2	7	60	88
Alaska California	29	2 34	10 59	33 815	34 922	185	14 472	24 657	338 12,221	248 13,140	_	0	3 3	8 12	11 31
Hawaii		0	4	5	19	_	12	19	295	298	_	Ō	2	13	10
Oregon [§] Washington	9	7 7	17 74	147 139	210 141	12 27	21 48	48 81	505 972	617 1,650	_	1 0	3 2	24 3	34 2
American Samoa	_	0	0	_	_	_	0	0	_	3	_	0	0	_	_
C.N.M.I. Guam	_	0	0	_	_	_	1	 15	_	43	_	0	0	_	_
Puerto Rico	_	2	15	27	82	8	4	16	109	140	—	0	1		—
U.S. Virgin Islands	—	0	0	—	_	_	2	7	54	65	N	0	0	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Me * Incidence data for reporting year 2008 and 2009 are provisional. † Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

MMWR

(20th week)				Hepat											
			Α					В					gionellosi	s	
	Current		vious veeks	Cum	Cum	Current		vious veeks	Cum	Cum	Current		/ious /eeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	16	37	89	822	1,325	16	71	197	1,492	1,840	45	48	152	840	1,047
New England Connecticut	_	2 0	8 4	34 12	62 11	_	1 0	4 3	17 7	41 14	3 2	2 0	18 5	31 19	57 12
Maine [§] Massachusetts	_	0 1	5 3	1 14	4 31	_	0 0	2 2	7 1	8 12	_	0 1	2 7	6	1 24
New Hampshire Rhode Island [§]	_	0	2 2	3 3	5 10	_	0	2 1	_2	3 3	1	0 0	5 14	3	7 9
Vermont§	_	0	1	1	1	_	0	1	_	1	_	0	1	1	4
Mid. Atlantic New Jersev	3	5 0	13 5	93 5	143 33	2	6 1	17 5	142 22	234 67	16	14 1	60 14	233 11	254 31
New York (Upstate)	2	1	4 6	26 28	31 44	—	1	11 4	33 29	34 50	11	5 2	24	85 35	65 32
New York City Pennsylvania	1	2 1	4	28 34	44 35	2	2	8	29 58	50 83	5	2 5	12 35	102	126
E.N. Central Illinois	_	4 1	12 4	90 21	195 75	1	9 2	21 7	195 24	247 89	9	8 1	41 13	134 8	227 32
Indiana	_	Ó	3	7	10	_	1	18	36	18	_	0	6	8	20
Michigan Ohio	_	1 1	5 4	33 24	70 22	1	3 2	8 13	60 57	71 57	9	2 4	16 18	27 86	63 100
Wisconsin W.N. Central	_	0 2	3 16	5 57	18 166	_	0 2	4 16	18 69	12 39	_	0 2	6 8	5 30	12 48
Iowa	_	0	5	13	78	—	0	3	11	11	_	0	2	10	8
Kansas Minnesota	_	0 0	1 12	6 12	10 18	_	0 0	2 11	4 11	6 4	_	0 0	1 4	2 5	1 4
Missouri Nebraska [§]	_	0 0	3 2	14 10	21 37	_	1 0	5 2	33 9	15 3	_	1 0	7 3	9 3	25 9
North Dakota South Dakota	_	0	2 1	2	2	_	0	1	1	_	_	0	3 1	1	1
S. Atlantic	4	7	15	199	171	7	18	31	470	463	12	9	22	197	206
Delaware District of Columbia	U	0	1 0	3 U	4 U	U U	0 0	1 0	U U	U U	3	0	2 2	6	5 7
Florida Georgia	1	4	8 4	96 31	71 26	5 2	6 3	11 9	156 72	164 85	3	3 1	7 5	71 26	69 17
Maryland§	2	Ó	4	19	18	_	2	6	41	43	2	2	9	44	54
North Carolina South Carolina§	1	1 0	7 3	22 13	26 6	_	1 1	19 5	119 21	47 36	1	0 0	7 1	30 2	11 4
Virginia [§] West Virginia	_	1 0	6 1	15	17 3	_	2 1	10 6	38 23	49 39	3	1 0	5 3	18	26 13
E.S. Central	1	1	5	21	39	_	8	13	147	179	2	2	5	45	65
Alabama [§] Kentucky	1	0 0	2 2	6 4	5 15	_	2 2	7 7	46 40	49 50	1	0 1	2 3	5 21	7 31
Mississippi Tennessee§	_	0 0	2 4	5 6	2 17	_	1 2	3 8	6 55	17 63		0 0	1 4	1 18	1 26
W.S. Central	_	3	43	73	131	2	11	99	214	378	_	2	21	40	35
Arkansas [§] Louisiana	_	0 0	1 2	4 2	4 7	1	1 1	5 4	14 21	26 52	_	0 0	2 2	2 1	5 5
Oklahoma Texas§	_	0 3	6 37	1 66	3 117	1	2 6	17 76	50 129	43 257	_	0 1	6 19	3 34	3 22
Mountain	_	3	31	74	102	2	3	10	66	90	1	2	8	41	38
Arizona Colorado	_	1 0	28 5	36 20	42 21	_	1 0	5 3	25 12	34 14	1	0 0	3 2	21 4	10 3
Idaho [§] Montana [§]	_	0 0	1 1	1 3	14	2	0 0	2 1		3	_	0 0	1 2	4	2 3
Nevada [§] New Mexico [§]	_	0	3 1	6 5	3 14	—	0 0	3 2	15 5	21 7	_	0 0	22	6	6 3
Utah	_	0	2	3	5	_	0	3	3	7	—	0	2	5	11
Wyoming [§] Pacific	8	0 8	0 25	181	3 316	2	0 7	1 36	2 172	4 169	2	0 3	1 12	1 89	117
Alaska California		0 6	25 1 25	3	2 255	2	0 5	1 28	172 3 127	109 6 118	1	0 3	1 9	2 69	1 88
Hawaii		0	2	138 4	6		0	1	3	3	—	0	1	1	4
Oregon [§] Washington	1	0 1	2 4	10 26	20 33	_	1 1	4 8	23 16	23 19	1	0 0	2 4	6 11	11 13
American Samoa	_	0	0	_	_	_	0	0	_	_	Ν	0	0	Ν	Ν
C.N.M.I. Guam	_	0	0	_	_	_	0	0			_	0	0	_	_
Puerto Rico U.S. Virgin Islands	_	0 0	2 0	7	16	_	0 0	5 0	3	26	_	0 0	0 0	_	_
5.5. trigin islands		0	<u> </u>				0	<u> </u>				0	· ·		

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 4, 2009, and June 28, 2008 (26th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Data for acute hepatitis C, viral are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

728

	Lyme disease							Malaria			Ме		cal diseas: All groups		/e [†]
			vious					vious					vious		
Reporting area	Current week	Med	veeks Max	Cum 2009	Cum 2008	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	veeks Max	Cum 2009	Cum 2008
United States	431	437	1,915	5,407	9,776	8	22	46	432	467	7	17	48	478	714
New England	45	55	837	611	3,868	_	1	5	15	24	_	0	4 1	15	19
Connecticut Maine [§]	34	12 6	264 73	156	1,594 70	_	0 0	4 1	4 1	5 1	_	0 0	1	1 2	1 3
Massachusetts	—	14	403	117	1,592	—	0	4	6	13	_	0	3 1	9 1	13
New Hampshire Rhode Island [§]	_	13 0	145 78	218 33	462 105	_	0 0	1	1 1	2 1	_	0 0	1	1	1 1
Vermont§	11	5	41	87	45	—	0	1	2	2	—	0	1	1	—
Mid. Atlantic New Jersey	333	218 27	1,401 231	3,276 509	3,620 1,643	3	5 0	17 4	102	118 23	_	2 0	5 1	49 2	75 10
New York (Upstate)	185	87	1,368	1,155	786	3	0	10	23	13	_	0	2	11	19
New York City Pennsylvania	148	3 53	54 338	1,612	198 993	_	3 1	11 3	61 18	65 17	_	0 1	2 4	9 27	13 33
E.N. Central	2	9	205	166	695	_	3	6	54	76	_	3	8	81	121
Illinois Indiana	_	0 0	13 8	4 9	42 8	_	1 0	5 1	20 8	36 3	_	1 0	6 4	17 21	44 16
Michigan	_	1	10	12	о 5	_	0	3	9	9	_	0	3	14	15
Ohio Wisconsin	2	0 9	6 187	10 131	8 632	_	0 0	2 2	14 3	18 10	_	0 0	3 1	23 6	29 17
WISCONSIN W.N. Central		9 7	336	71	143	2	1	2 10	27	21	_	1	9	39	65
Iowa	—	1	9	29	53		Ó	3	5	2	_	Ó	1	4	12
Kansas Minnesota	_	0 2	4 326	8 28	5 81	2	0	2 8	2 12	3 6	_	0	2 4	8 8	3 18
Missouri	—	0	1	2	1	—	0	2	5	5	—	0	2	13	21
Nebraska [§] North Dakota	_	0 0	2 10	3	2	_	0	1 0	_2	5	_	0	1 3	4	9 1
South Dakota	_	Ő	1	1	1	_	Ő	ĩ	1	_	_	Ő	1	2	1
S. Atlantic Delaware	49 8	65 12	223 36	1,155 312	1,335 390	1	6 0	15 1	148 1	125 1	2	2 0	9 1	91 2	98 1
District of Columbia	—	0	5	—	24	_	0	2	_	—	_	0	0	—	_
Florida Georgia	4 2	1 0	6 6	19 20	15 16	1	1	7 4	38 33	22 29	1	1 0	4 2	31 18	34 12
Maryland§	27	27	163	547	620	_	1	8	39	37	_	0	1	4	12
North Carolina South Carolina [§]	4 1	1 0	7 3	34 13	2 11	_	0 0	5 1	18 1	11 4	1	0 0	5 1	16 7	8 15
Virginia§	3	12	61	176	197	_	1	4	17	20	_	0	2	9	13
West Virginia	—	1	17	34	60	—	0	1	1	1	_	0	2	4	3
E.S. Central Alabama [§]	_	0 0	5 1	10 1	19 8	_	0 0	2 1	12 3	8 3	_	0	3 1	16 4	37 4
Kentucky	—	0	2	1	1	—	0	2	5	3	—	0	1	3	7
Mississippi Tennessee [§]	_	0 0	0 3	8	1 9	_	0 0	1 2	4	2	_	0 0	1	1 8	9 17
W.S. Central	_	2	21	18	40	_	1	10	11	23	_	1	12	42	75
Arkansas§ Louisiana	_	0 0	0 1	_	_	_	0	1	1	2	_	0	2 3	5 9	10 17
Oklahoma	—	0	2			_	0	2	1	2	_	0	3	3	10
Texas [§]	_	2	21	18	40	_	1	10	9	19	_	1	9	25	38
Mountain Arizona	1	1 0	13 2	15 2	15 2	_	0 0	3 2	6 2	13 5	1	1 0	4 2	41 8	39 5
Colorado	—	0 0	1	1 5	2 3	—	0	1	2	3	1	0	2	13	8
ldaho [§] Montana [§]	_	0	13	5 1	2	_	0	1 0	1	_	_	0	2	5 4	4 4
Nevada [§] New Mexico [§]	1	0 0	2 2	6	2 3	_	0 0	1	_	4 1	_	0 0	2 1	3 3	7 4
Utah	_	0	2	_		_	0	1	1	_	_	0	1	1	5
Wyoming§	—	0	1	—	1	—	0	0	—	—	—	0	2	4	2
Pacific Alaska	1	3 0	13 2	85 1	41 1	_2	3 0	10 1	57 1	59 3	4	4 0	14 2	104 2	185 3
California	1	2	6	75	27	2	2	8	45	46	4	2	8	69	143
Hawaii Oregon [§]	N	0 0	0 3	N 6	N 13	_	0 0	1 2	1 5	2 4	_	0 1	1 7	3 21	2 21
Washington	_	0	12	3	_	_	0	3	5	4	_	0	6	9	16
American Samoa C.N.M.I.	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
Guam	_	0	0	_	_	_	0	2	_	1	_	0	0	_	_
Puerto Rico	N	0	0	N	N	—	0	1	1	2	_	0	1	—	2
U.S. Virgin Islands	N	0	0	N	N	_	0	0	_	_	_	0	0	—	—

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. * Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(26th week)*															
		Deer	Pertussis	5				abies, anin	nal		R		untain spo	tted fever	
	Current		vious veeks	Cum	Cum	Current		vious veeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	74	242	1,697	5,426	3,827	40	69	122	1,624	1,974	33	28	179	516	551
New England Connecticut	_	17 0	35 4	232 13	439 32	4	8 3	15 10	166 73	186 92	_	0 0	2 0	4	3
Maine [†]	_	1	10	57	14	3	1	5	26	28	_	0	2	4	—
Massachusetts New Hampshire	_	11 1	30 6	105 38	346 13	_	0 1	0 7	 19	17	_	0 0	1 0	_	1 1
Rhode Island [†]	_	1	6	11	28	1	0	3	20	16	_	0	2	_	1
Vermont [†]		0	2	8	6		1	6	28	33	_	0	0	_	_
Mid. Atlantic New Jersev	13	24 3	64 12	486 56	437 85	15	16 0	30 0	310	407	1	1 0	29 6	21	50 34
New York (Upstate)	6	6	41	95	135	15	8	20	192	207	1	0	29	2	4
New York City Pennsylvania	7	0 11	21 33	47 288	45 172	_	0 7	2 17	118	10 190	_	0 0	4 2	12 7	6 6
E.N. Central	12	44	238	1,170	698	4	2	28	69	71	_	1	15	21	38
Illinois Indiana	_	14 3	45 158	234 104	82 22	4	1 0	20 6	26 6	27 1	_	1 0	10 3	9 1	27 1
Michigan	_	9	21	242	95	_	1	9	22	26	_	0	1	3	2
Ohio Wisconsin	12	15 4	57 10	535 55	453 46	N	0 0	7 0	15 N	17 N	_	0 0	3 0	8	8
Wisconsin W.N. Central	_	32	872	917	336	1	5	17	126	124	_	3	33	58	135
Iowa	_	5	21	81	48		0	5	9	10	_	0	1	1	5
Kansas Minnesota	_	3 0	12 808	94 165	30 95	_	1 0	6 11	49 20	39 18	_	0 0	1 0	1	_
Missouri	—	14	51	479	121	—	1	8	17	14	—	3	32	52	125
Nebraska† North Dakota	_	4 0	32 24	86 1	30 1	_	0 0	2 9	4	18 13	_	0	4 1	4	2
South Dakota	—	0	10	11	11	1	0	4	27	12	—	0	0	—	3
S. Atlantic Delaware	31	26 0	71 3	758 6	366 5	13	25 0	95 0	714	929	16	15 0	72 5	271 3	138 7
District of Columbia	_	0	2	_	1	_	0	0	_	_	_	0	1	—	3
Florida Georgia	6	8 3	33 9	256 79	87 33	_	0 5	79 52	79 154	138 201	_	0 1	3 5	4 16	3 31
Maryland [†]	2	3	10	49	50	_	6	13	146	234	1	1	7	23	22
North Carolina South Carolina [†]	21 1	0 3	65 14	199 93	76 51	N	4 0	4 0	N	N	13	10 1	55 9	188 12	22 14
Virginia [†]	_	3	24	70	57	10	11	24	276	298	1	2	15	23	31
West Virginia	1	0	2	6	6	3	1	6	59	58	1	0	1	2	5
E.S. Central Alabama [†]	5	12 3	33 19	344 124	131 19	_	3 0	7 0	63	88	2 1	4 1	23 7	87 18	91 25
Kentucky	1	4	15	106	25	—	1	4	29	16	—	0	0	4	1 4
Mississippi Tennessee [†]	4	1 2	5 14	23 91	56 31	_	0 2	2 6	34	2 70	1	0 3	3 19	4 65	4 61
W.S. Central	_	40	389	764	432	_	0	9	27	52	13	2	161	45	80
Arkansas† Louisiana	_	2 2	38 7	34 43	40 24	_	0 0	5 0	22	34	8	0 0	61 2	22 2	8 3
Oklahoma	_	0	45	15	13	_	0	9	4	16	5	0	98	10	54
Texas [†]		33	304	672	355	_	0	1 9	1	2	_	1	6	11	15
Mountain Arizona	11	15 3	31 8	402 93	463 134	N	2 0	0	48 N	32 N	_	1 0	3 2	7 2	14 5
Colorado Idaho†	10	4	12 5	148 39	74 20	_	0	0 2	_	2	_	0	1	_	_
Montana [†]	_	0	4	9	60	_	Ō	4	13	1	_	0	1	3	2
Nevada† New Mexico†	1	0 1	3 10	7 30	18 25	_	0	5 2	1 15	3 18	_	0 0	2 1	1	1
Utah	_	4	19	75	124	_	0	6	2	2	_	0	1	1	2
Wyoming [†]	_	0	2	1	8	_	0	4	17	6	_	0	2	_	4
Pacific Alaska	_2	21 3	98 21	353 28	525 44	3	4 0	13 2	101 9	85 12	1 N	0 0	1 0	2 N	2 N
California	—	5	19	58	278	3	4	12	92	71	1	0	1	2	_
Hawaii Oregon [†]	_	0 3	3 14	16 110	6 81	_	0 0	0 2	_	2	<u>N</u>	0 0	0 1	N	N 2
Washington	2	6	76	141	116	—	0	0	—	—	—	0	0	—	—
American Samoa C.N.M.I.	_	0	0	_	_	N	0	0	N	N	N	0	0	N	N
Guam	_	0	0	_	_	_	0	0	_	_	Ν	0	0	N	Ν
Puerto Rico	_	0	1	1	_	1 N	1 0	5 0	17 N	29 N	N N	0 0	0 0	N	N
U.S. Virgin Islands	_	0	0			N	U	0	IN	IN	IN	0	U	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(26th week)		s	almonello	sis		Shic	la toxin-pi	oducina	E. coli (ST	EC)†		s	higellosis		
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	vious				• • •	ious					/ious		
Denti	Current	-	veeks	Cum	Cum	Current	52 W		Cum	Cum	Current	_	/eeks	Cum	Cum
Reporting area United States	week 570	Med 786	Max 2,318	2009 15,857	2008 17,824	week 53	Med 75	Max 255	2009 1,399	2008 1,703	week 167	Med 411	Max 1,268	2009 7,057	2008 8,571
<b>New England</b> Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§]	5 — — 1 3	26 0 2 18 3 2	209 183 8 51 33 9	727 183 51 263 139 63	1,164 491 66 470 63 36		3 0 1 1 0	43 43 3 11 3 1	88 43 9 15 16	114 47 3 40 12 7		3 0 2 0 0	19 14 6 9 1 1	67 14 2 40 1 7	110 40 3 57 2 7
Vermont [§] Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1 36  22 2 12	1 84 13 26 19 29	7 201 55 65 49 78	28 1,769 122 490 453 704	38 2,232 535 529 517 651	5 5 1	0 6 1 3 1 0	6 27 12 12 5 8	5 96 14 44 32 6	5 179 61 46 24 48	$\frac{10}{3}$	0 54 18 6 10 18	2 93 38 23 23 40	3 1,268 249 100 209 710	1 1,089 290 319 420 60
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	53 — — 52 1	87 25 7 18 27 13	194 50 53 38 49 30	1,952 460 127 405 684 276	2,176 661 187 396 592 340	4  4	12 1 3 3 3	74 10 14 43 15 16	221 34 23 57 56 51	259 39 18 56 65 81	25 — — 24 1	86 15 2 5 42 11	132 34 39 24 80 42	1,358 284 27 118 701 228	1,497 491 362 49 430 165
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	33 7 5 2 4 15	50 7 12 11 5 0 3	148 15 29 69 48 41 30 22	1,183 188 163 280 209 192 32 119	1,158 203 176 278 303 113 21 64	14 10 1 2 1	12 3 1 2 2 0 0	58 21 7 21 11 30 28 4	231 69 19 64 41 31 3 4	271 64 22 53 78 32 1 21	2 2	14 3 3 3 0 0 0	49 12 11 25 33 3 9 1	363 42 122 34 151 9 3 2	430 75 8 113 132  28 74
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	239 — 122 28 17 27 9 15 21	236 2 0 100 39 16 28 17 19 3	457 9 2 174 96 35 106 57 88 10	4,303 33  1,849 746 300 684 263 336 92	4,236 62 37 1,828 759 347 378 360 363 102	12 1 2 2 1 3 - 2 1	13 0 2 1 2 0 3 0	48 2 1 10 8 11 21 3 27 3	291 7 81 32 40 66 9 47 9	296 7 4 35 45 28 19 63 21	38 — 8 7 7 14  2 	47 0 10 13 5 6 4 4 0	85 8 26 30 12 27 17 59 3	1,117 40 215 307 162 233 65 90 5	1,713 6 8 467 692 31 51 354 84 20
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	29 6 13 1 9	49 16 10 12 14	140 49 18 57 62	949 264 204 204 277	1,119 288 183 343 305	3  -  - 3	5 1 2 0 2	12 4 7 1 6	92 23 25 6 38	114 38 23 3 50	6  1  5	23 4 2 1 14	58 12 25 6 48	477 80 125 14 258	1,047 251 186 235 375
<b>W.S. Central</b> Arkansas [§] Louisiana Oklahoma Texas [§]	35 16 8 11	83 12 16 14 57	1,328 39 54 102 1,199	1,171 224 236 243 468	2,151 211 373 246 1,321	1 1 —	5 0 0 3	139 5 1 82 55	53 9  9 35	151 26 4 14 107	45 7 4 12 22	89 10 6 4 61	967 27 26 61 889	1,335 177 72 110 976	1,747 195 324 47 1,181
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	32 6 22 3  1 	55 19 12 3 2 4 6 6 1	109 43 23 12 7 12 25 19 5	1,149 423 280 73 49 111 102 89 22	1,454 402 382 77 47 110 260 138 38	2 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	10 1 2 0 1 1 0	40 4 18 15 3 4 9 2	172 21 77 27 6 11 16 13 1	195 29 55 38 19 9 20 18 7	22 21 — — — —	27 17 2 0 2 3 1 0	54 35 11 2 5 13 12 3 1	531 395 41 3 11 31 46 4 	339 152 38 5 2 103 26 10 3
Pacific Alaska Callfornia Hawaii Oregon [§] Washington	108  96 4  8	121 1 93 5 7 11	537 4 516 15 20 85	2,654 25 2,057 113 181 278	2,134 21 1,553 107 188 265	12 6 — 6	9 0 5 0 1 3	31 1 15 2 7 16	155 — 94 2 12 47	124 3 68 5 16 32	19 	29 0 25 1 1 2	82 1 75 3 10 13	541 2 431 13 17 78	599 
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	  	0 0 9 0	1 2 40 0		1 8 290 —		0 	0 0 0 0	 			0 0 0 0	2 1 4 0	3  -  2  -	1 13 10 —

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	s	Streptococcal	diseases, inv	asive, group A		Streptococc		ae, invasive di Age <5 years	sease, nondru	ig resistant†
	Current	Prev 52 w	ious	Cum	Cum	Current	Prev 52 w	ious	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	44	96	239	3,029	3,402	6	33	122	920	1,044
New England	2	5	28	169	249	_	1	12	24	53
Connecticut Maine [§]	_	0 0	21 3	49 10	66 17	_	0 0	11	2	1
Massachusetts	_	2	10	60	121	—	1	2	15	41
New Hampshire Rhode Island [§]	1	1 0	4 2	28 9	16 19	—	0	1 2	5	7 4
Vermont§	1	0	3	13	10	_	0	1	2	-4
Mid. Atlantic	11	18	38	588	713	1	4	33	137	135
New Jersey New York (Upstate)	8	1 6	6 25	5 223	129 225	1	1 2	4 17	14 71	39 60
New York City		4	12	124	133	_	0	31	52	36
Pennsylvania	3	6	18	236	226	N	0	2	N	N
E.N. Central	1	16	42	601	680	1	5	18	134	191
Illinois Indiana	_	4 3	12 23	163 103	188 86	_	1 0	5 13	15 16	54 20
Michigan		3	11	100	116		1	5	42	53
Ohio Wisconsin	1	4 2	13 10	159 76	185 105	1	1	6 4	44 17	35 29
Wisconsin W.N. Central	13	6	37	272	256	_	2	11	69	29 49
lowa	—	0	0	_	_	_	0	0	_	_
Kansas		1	5	37	28	N	0	1	N	N
Minnesota Missouri	13	0 2	34 8	118 61	122 62	_	0 1	7 4	31 26	11 22
Nebraska§	—	1	3	29	23	—	0	1	4	6
North Dakota South Dakota	_	0 0	4	10 17	8 13	_	0	3 2	4 4	5 5
S. Atlantic	10	22	47	669	669	2	6	16	193	202
Delaware		0	1	8	6	_	0	0	_	—
District of Columbia Florida	2	0 6	2 12	162	7 147	N	0 1	0 6	N 46	N 39
Georgia	3	5	13	154	151	_	2	6	40	54
Maryland§	3	3	10	100	122	1	1	3	40	39
North Carolina South Carolina [§]	1	2 1	12 5	73 41	86 40	N 1	0 1	0 6	N 32	N 32
Virginia§		3	9	103	85	_	Ó	4	18	33
West Virginia	1	1	4	28	25	—	0	2	8	5
E.S. Central Alabama [§]	1 N	4 0	10 0	124 N	114 N	N	1 0	6 0	35 N	56 N
Kentucky	_	1	5	23	24	N	0	0	N	N
Mississippi Tennessee [§]	N	0 3	0 9	N 101	N 90	—	0 1	2 6	35	7 49
W.S. Central	1 3	9	9 79	262	90 281		6	46	172	49 154
Arkansas§	1	0	2	10	201		0	40	17	9
Louisiana	_	0	3	9	11		0	3	13	8
Oklahoma Texas [§]	2	2 6	20 59	92 151	66 197	1	1 4	7 34	33 109	46 91
Mountain	2	9	22	265	368	_	4	16	138	172
Arizona	2	3	7	90	125	_	2	10	78	79
Colorado Idaho [§]	_	3 0	9 2	96 3	93 12	_	1 0	4	28 6	39 3
Montana [§]	Ν	0	0	N	N	N	0	ō	Ň	N
Nevada [§] New Mexico [§]	—	0 2	1 7	5 47	6 93	_	0	1 4	 15	2 25
Utah	_	1	6	23	93 34	_	0	4	15	23
Wyoming§	_	0	1	1	5	_	0	1	—	1
Pacific	1	3	9	79	72	—	0	3	18	32
Alaska California	N	0 0	4	10 N	16 N	N	0 0	2 0	13 N	21 N
Hawaii	1	3	8	69	56		0	2	5	11
Oregon [§] Washington	N	0	0	N N	N N	N N	0 0	0 0	N N	N N
American Samoa		0	0		30	N	0	0	N	N
C.N.M.I.	_	_	_	_				_		
Guam	N	0 0	0 0	N	N	N	0 0	0 0	N	N
Puerto Rico										

C.N.M.I.: Commonwealth of Northern Mariana Islands.

 U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2008 and 2009 are provisional.
 * Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available. (NNDSS event code 11717). § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	Streptococcus pneumoniae, invasive disease, drug resistant [†]														
			All ages				Aç	- ged <5 yea	irs		Sy	philis, pr	mary and	l seconda	ry
	Current	Prev 52 w		Cum	Cum	Current		vious veeks	Cum	Cum	Current		ious eeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	14	56	276	1,693	1,955	3	9	21	259	285	77	263	452	6,157	6,098
New England Connecticut	_	1 0	48 48	30	41	_	0 0	5 5	1	5	6	5 1	15 5	155 32	155 10
Maine [§] Massachusetts	_	0 0	2 1	8 1	13	_	0 0	1	1	_	6	0 3	2 11	1 108	6 121
New Hampshire	_	0	3	5	_	_	0	0	_	_	—	0	2	10	7
Rhode Island [§] Vermont [§]	_	0 0	6 1	7 9	15 13	_	0 0	1 0	_	3 2	_	0 0	5 2	4	6 5
Mid. Atlantic	2	4	14	101	199	_	0	3	19	16	22	32	51	901	850
New Jersey New York (Upstate)	1	0 1	0 10	43	38	_	0 0	0 2	10	5	2	4 2	13 8	101 55	102 69
New York City Pennsylvania	1	0 1	4 8	2 56	84 77	_	0 0	2 2	9	11	15 5	22 6	36 12	567 178	531 148
E.N. Central	6	9	41	376	431	1	1	7	52	58	1	24	44	462	543
Illinois Indiana	Ν	0 2	0 32	N 118	N 149	N	0 0	0 6	N 17	N 18	1	9 2	19 10	126 75	206 68
Michigan	_	0	2	16	15	_	0	1	2	2	—	4	18	116	102
Ohio Wisconsin	6	7 0	18 0	242	267	1	1 0	4 0	33	38	_	6 1	15 4	121 24	143 24
W.N. Central	_	3	161	87	142	_	1	3	20	28	_	6	14	148	203
lowa Kansas	_	0 1	0 5	38	57	_	0 0	0 2	13	3	_	0 0	2 3	12 13	10 17
Minnesota Missouri	_	0	156 5	37	20 60	_	0 0	3 1	5	20 2	_	2 3	6 10	29 76	47 123
Nebraska§	_	Ó	0	_	—	—	0	Ó	—	—	—	0	2	14	6
North Dakota South Dakota	_	0 0	3 2	10 2	2 3	_	0 0	0 2	2	3	_	0 0	1 1	3 1	_
S. Atlantic	6	25	53	804	768	2	4	14	119	116	16	63	262	1,481	1,291
Delaware District of Columbia	N	0 0	2 0	10 N	2 N	N	0 0	0 0	N	N	2	0 3	3 9	17 88	8 64
Florida Georgia	3 2	15 8	36 25	490 226	414 269	2	3 1	13 5	79 33	72 37	1	20 14	32 227	475 292	496 231
Maryland§	_	0	1	4	4	_	Ö	0	_	1	4	6	16	143	165
North Carolina South Carolina§		0 0	0 0	<u>N</u>	<u>N</u>	N	0 0	0 0	<u>N</u>	<u>N</u>	7 2	8 2	19 6	264 56	145 44
Virginia [§] West Virginia	N 1	0 2	0 13	N 74	N 79	N	0	0 3	N 7	N 6	_	5 0	16 1	143 3	133 5
E.S. Central	_	5	25	181	221		1	3	26	40	10	22	36	516	517
Alabama [§] Kentucky	N	0 1	0 5	N 51	N 54	N	0	0 2	N 7	N 9	1	8 1	15 10	179 26	227 45
Mississippi Tennessee§	_	0 3	3 22	130	26 141	_	0 0	1 3	 19	8 23	3 6	3 8	18 19	98 213	70 175
W.S. Central	_	1	6	56	71		0	3	10	12	17	51	80	1,243	1,014
Arkansas [§] Louisiana	_	0 1	5 5	33 23	13 58	_	0 0	3 1	7 3	3 9	2	4 14	35 40	99 291	73 249
Oklahoma	Ν	0	0	N	N	Ν	0	0	N	N	_	1	7	29	41
Texas [§] Mountain	_	0 2	0 7	 56	 81	_	0 0	0 3		9	13 4	31 8	46 18	824 148	651 322
Arizona	—	0	0		—	_	0	0	—	_	—	3	11	21	164
Colorado Idaho [§]	N	0 0	0 1	N	N	N	0 0	0 1	N	N	_	1 0	5 2	45 3	89 1
Montana [§] Nevada [§]	_	0 1	1 4	27	40	_	0 0	0 2	6	4	3	0 1	7 7	 55	38
New Mexico§	_	0	0	_	_	_	0	0	_	_	1	1	5	23	15
Utah Wyoming [§]	_	1 0	6 2	22 7	41	_	0 0	3 1	4 1	5	_	0 0	2 1	1	13 2
Pacific	—	0	1	2	1	_	0	1	1	1	1	46	67	1,103	1,203
Alaska California	N	0 0	0 0	N	N	N	0 0	0 0	N	N	_	0 42	1 60	1,011	1,088
Hawaii Oregon§	N	0	1 0	2 N	1 N	N	0 0	1 0	1 N	1 N	1	0	3 4	16 21	12 6
Washington	Ν	0	0	Ν	N	Ν	0	0	Ν	Ν	<u> </u>	2	9	55	97
American Samoa C.N.M.I.	N	0		N	N	N	0	0	N	N	_	0	0	_	_
Guam Puerto Rico	_	0 0	0 0	_	—	_	0 0	0 0	—	_	3	0 3	0 11	107	 88
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_		0	0	107	

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2008 and 2009 are provisional.
 † Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).
 § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

						West Nile virus disease [†]										
		Varic	ella (chick	enpox)		Neuroinvasive Nonneuroinvasive§										
	Previous					Previous					Previous					
Reporting area	Current week	52 v	weeks Max	Cum 2009	Cum 2008	Current week	52 w Med	veeks Max	Cum 2009	Cum 2008	Current week	52 w	veeks Max	Cum 2009	Cum 2008	
United States	101	449	1,035	10,936	18,764		1	75	4	2008	week	0	77	2009	43	
New England	1	14	46	161	978	_	0	2	_	<u> </u>	_	0	1		2	
Connecticut	—	3	21	_	484	—	Ō	2	—	—	—	0	1	—	2	
Maine [¶] Massachusetts	_	0 0	11 0	_	157	_	0 0	0 1	_	_	_	0	0	_	_	
New Hampshire	1	4	11	114	163	_	0	0	_	_	_	0	0	_	_	
Rhode Island [¶] Vermont [¶]	_	0 3	1 17	4 43	174	_	0	1 0	_	_	_	0	0	_	_	
Mid. Atlantic	9	38	58	925	1,475	_	0	8	_	_	_	0	4	_	_	
New Jersey New York (Upstate)	N N	0 0	0	N N	N N	_	0 0	2 5	_	_	_	0 0	1 2	_	_	
New York City	_	0	0	_	_	_	0	2	_	_	_	0	2	_	_	
Pennsylvania	9	38	58	925	1,475	—	0	2	—	—	—	0	1	—	—	
E.N. Central Illinois	10	151 33	254 73	3,896 822	4,587 635	_	0	8 4	_	_	_	0	3 2	_	_	
Indiana	_	0	19	168	_	_	0	1	_	_	_	0	1	_	—	
Michigan Ohio	8	48 42	90 91	1,219 1,342	1,954 1,490	_	0	4 3	_	_	_	0 0	2	_	_	
Wisconsin	2	14	53	345	508	—	Õ	2	_	_	_	Õ	1	—	_	
W.N. Central lowa	2 N	22 0	114 0	626 N	737 N	_	0	6 2	_	_2	_	0	21 1	1	9	
Kansas		6	22	172	295	_	0	2	_	2	_	0	3	_	4	
Minnesota	_	0	0	400	414	_	0	2	_	—	—	0	4	_	_	
Missouri Nebraska [¶]	N	11 0	51 0	400 N	414 N	_	0	3 1	_	_	_	0 0	6	_	_	
North Dakota	2	0	108	54	—	—	0	2	_	—	—	0	11	_	4	
South Dakota S. Atlantic	16	0 57	4 146	1,278	28 2,971	_	0 0	5 4	_	2	_	0 0	6 4	1	1	
Delaware		0	4	2	21	_	0	0	_		_	0	1	_	_	
District of Columbia Florida	11	0 28	3 67	846	17 1,077	_	0	2 2	_	_	_	0 0	1 0	_	_	
Georgia	N	0	0	N	1,077 N	_	0	1	_	_	_	0	1	_	_	
Maryland [¶] North Carolina	N N	0 0	0 0	N N	N N	_	0 0	2	_	1	_	0	3		—	
South Carolina [¶]		5	54	154	555	_	0	ò	_	_	_	ŏ	1	_	_	
Virginia [¶] West Virginia	5	7 10	119 32	28 248	877 424	_	0	0	_	1	—	0	1 0	—	_	
E.S. Central	2	14	28	364	810	_	0	7	_	3	_	0	9	_	8	
Alabama [¶]	2	14	28	363	800	_	0	3	_	—	_	0	2	_	1	
Kentucky Mississippi	N	0 0	0 1	N 1	N 10	_	0 0	1 4	_	1	_	0 0	0 8	_	5	
Tennessee [¶]	Ν	0	0	Ν	N	_	0	2	_	2	_	0	3	_	2	
W.S. Central Arkansas ¹	60	93 4	747 47	2,890 96	5,770 420	_	0	8 1	2 1	8 3	_	0	7 1	_	8	
Louisiana	2	1	5	43	50	_	0	3	_	_	_	0	5	_	1	
Oklahoma Texas¶	N 58	0 85	0 721	N 2,751	N 5,300	_	0	1 6	1	2 3	_	0 0	1 4	_	3 4	
Mountain	1	29	83	735	1,366	_	0	12	2	2	_	0	22	1	11	
Arizona	_	0	0	_	<i>′</i> —	—	Ō	10	1	1	—	0	8	_	—	
Colorado Idaho¶	1 N	13 0	44 0	327 N	553 N	_	0	4	1	1	_	0	10 6	_	8 1	
Montana [¶]		3	27	105	186	_	0	0	_	_	_	0	2	_	—	
Nevada [¶] New Mexico [¶]	N	0 4	0 20	N 114	N 138	_	0 0	2 1	_	_	_	0 0	3 1	1	_	
Utah	_	10	31	189	480	—	0	2	_	—	_	0	5	—	1	
Wyoming [¶]	_	0 2	1 7		9 70	_	0 0	0	_		_	0	2	_	1	
Pacific Alaska	_	1	6	61 40	30	_	0	38 0	_	4	_	0 0	23 0	_	5	
California	_	0	0			_	0	37	_	4	_	0	20	_	5	
Hawaii Oregon [¶]	N	1 0	4 0	21 N	40 N	_	0 0	0 2	_	_	_	0 0	0 4	_	_	
Washington	Ν	0	0	Ν	N	—	0	1	_	—	—	0	1	—	—	
American Samoa C.N.M.I.	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_	
Guam	_	1	3	_	55	_	0	0	_	_	_	0	0	_	_	
Puerto Rico	1	7	17	130	341	—	0	0	_	_	_	0	0	—	—	
U.S. Virgin Islands		0	0			_	0	0				0	0	_	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance).

Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

[§] Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

#### TABLE III. Deaths in 122 U.S. cities,* week ending July 4, 2009 (26th week)

		All cau	uses, by a	age (year	rs)				All causes, by age (years)						
Reporting area	All Ages				Reporting area	All Ages	≥65	45–64 25-	25–44	5–44 1–24	<1	P&I [†] Total			
New England	434	290	108	24	9	3	38	S. Atlantic	1,068	613	299	90	34	32	57
Boston, MA	108	70	28	7	2	1	6	Atlanta, GA	138	75	35	18	4	6	8
Bridgeport, CT	U	U	U	U	U	U	U	Baltimore, MD	165	83	62	10	8	2	15
Cambridge, MA	12	9	3	_	_	—	1	Charlotte, NC	89	51	26	7	_	5	6
Fall River, MA	25 58	19 36	5 12	1 5	5	_	3 6	Jacksonville, FL Miami, FL	95 121	58 76	24 28	11 9	2 6	2	4 11
Hartford, CT Lowell, MA	58 12	30	4	<u> </u>	5	_	ю 1	Norfolk, VA	36	23	∠8 9	9	0	2	
Lynn, MA	5	5	-	_	_	_	1	Richmond, VA	51	32	14	1	_	4	_
New Bedford, MA	23	19	3	1	_	_	2	Savannah, GA	50	32	11	3	3	1	5
New Haven, CT	15	10	3	_	_	2	1	St. Petersburg, FL	45	28	10	7	_	_	2
Providence, RI	52	28	20	3	1	_	2	Tampa, FL	157	105	33	11	5	3	5
Somerville, MA	1	1	_	_	_	_	_	Washington, D.C.	112	46	43	11	6	6	_
Springfield, MA	43	30	12	1	_	—	4	Wilmington, DE	9	4	4	1	_	—	1
Waterbury, CT	20	15	3	2	—	—	1	E.S. Central	680	415	177	41	23	24	51
Worcester, MA	60	40	15	4	1	_	10	Birmingham, AL	101	64	30	5	—	2	10
Mid. Atlantic	1,672	1,124	401	90	31	24	99	Chattanooga, TN	60	40	15	3	1	1	4
Albany, NY	50	38	9	1	—	2	3	Knoxville, TN	78	42	24	4	5	3	4
Allentown, PA	25	17	7	1		—	2	Lexington, KY	54	35	14	1	_	4	_
Buffalo, NY	72	46	16	6	4	—	5	Memphis, TN	110	65	28	7	6	4	9
Camden, NJ	29	19 4	9 2	1	_	_	3	Mobile, AL	79	60 27	9	8 2	2	_	6
Elizabeth, NJ	7	-		1 1	1	1	3	Montgomery, AL	41	27	11		1 8	10	6 12
Erie, PA	54 22	41 13	10 9	I	I	_	0 1	Nashville, TN W.S. Central	157 852	82 515	46 218	11 67	35	16	47
Jersey City, NJ New York City, NY		501	9 191	43	7	11	34	Austin, TX	852 70	515	12	2	35	10	47
Newark, NJ	25	11	10	43	1	2	1	Baton Rouge, LA	40	28	7	2 5	_		_
Paterson, NJ	6	5		1	_	_	3	Corpus Christi, TX	40	32	6	2	_	_	1
Philadelphia, PA	326	200	81	25	13	5	10	Dallas, TX	174	90	59	12	7	5	9
Pittsburgh, PA§	26	21	4	1	_	_	6	El Paso, TX	99	71	18	6	3	1	2
Reading, PA	26	18	5	2	_	1	_	Fort Worth, TX	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ů	Ū
Rochester, NY	105	76	24	1	3	1	13	Houston, TX	304	160	91	28	16	9	21
Schenectady, NY	20	16	3	1	_	_	1	Little Rock, AR	U	U	U	U	U	U	U
Scranton, PA	21	16	5	_	_	_	_	New Orleans, LA	U	U	U	U	U	U	U
Syracuse, NY	59	46	10	1	1	1	3	San Antonio, TX	U	U	U	U	U	U	U
Trenton, NJ	19	15	3	1	—	_	1	Shreveport, LA	22	17	2	_	3	_	2
Utica, NY	16	14	1	1	_	_	1	Tulsa, OK	103	65	23	12	3	—	5
Yonkers, NY	11	7	2	1	1	—	4	Mountain	924	585	234	50	34	20	56
E.N. Central	1,365	915	305	67	38	40	89	Albuquerque, NM	113	61	34	12	5		4
Akron, OH	52	34	12	3	1	2	4	Boise, ID	42	34	6	1	_	1	3
Canton, OH	33	24	5	1	1	2	1	Colorado Springs, CO	75	45	21	5	3	1	2
Chicago, IL	233	133	64	18	10	8	26	Denver, CO	67	39	18	2	4	4	4
Cincinnati, OH	70	43	16 40	6	1 6	4 1	4 7	Las Vegas, NV	244	164	64 4	13 3	1 3	2	22 3
Cleveland, OH Columbus, OH	194 U	135 U	40 U	12 U	Ŭ	U	Ű	Ogden, UT Phoenix, AZ	36 133	26 72	4 37	3 9	3 8	7	3
Dayton, OH	99	71	21	4	1	2	5	Pueblo, CO	31	24	6		1	_	1
Detroit, MI	Ű	Ű	Ŭ	Ū	Ů	Ú	Ŭ	Salt Lake City, UT	101	64	25	2	7	3	6
Evansville, IN	50	32	12	_	2	4	2	Tucson, AZ	82	56	19	3	2	2	4
Fort Wayne, IN	81	61	13	3	2	2	4	Pacific	1,341	891	328	75	30	17	116
Gary, IN	7	3	2	_	1	1	_	Berkeley, CA	11	6	5	_	_	_	2
Grand Rapids, MI	52	37	10	3	1	1	1	Fresno, CA	122	78	29	7	8	_	11
Indianapolis, IN	152	89	40	7	9	7	15	Glendale, CA	33	27	4	2	_	_	3
Lansing, MI	46	36	10	_	—	—	3	Honolulu, HI	56	41	13	2	—	_	8
Milwaukee, WI	55	35	15	4	1	_	3	Long Beach, CA	62	39	15	5	—	3	10
Peoria, IL	53	40	8	1	1	3	5	Los Angeles, CA	211	136	41	21	8	5	24
Rockford, IL	46	30	11	3	—	2	2	Pasadena, CA	15	12	2			1	1
South Bend, IN	28	22	5	1		—	2	Portland, OR	78	54	19	2	2	1	4
Toledo, OH	83	63	18	1	1		3	Sacramento, CA	137	89	35	11	1	1	8
Youngstown, OH	31	27	3		_	1	2	San Diego, CA	117	85	29	1	2		9
W.N. Central	356	239	76	28	6	7	18	San Francisco, CA	85	55	23	3	1	3	9
Des Moines, IA	U	U	U	U	U	U	U	San Jose, CA	145	95	38	7	3	2	14
Duluth, MN	19	13	6	_	_	—	_	Santa Cruz, CA	22	14	7	1	_	_	_
Kansas City, KS	13	7	6	3	_		1	Seattle, WA	89	57	23	6	2	1	6
Kansas City, MO	63 37	42 29	15 3	3	1	3	2 3	Spokane, WA Tacoma, WA	47	31 72	12 33	3 4	1 2	_	1 6
Lincoln, NE Minneapolis, MN	37 55	29 31	3 15	4 6	1	2	3	Tacoma, WA	111	5,587	2,146	532	240 240	183	571
Omaha, NE	52	39	15	3			3		8,692	5,507	2,140	552	240	103	571
St. Louis, MO	33	22	4	5	1	1	2	1							
St. Paul, MN	35	27	7	1	_	_	2	1							
Wichita, KS	49	29	10	6	3	1	1	1							
		25	10	<u> </u>				-				_			

U: Unavailable. —:No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. * Pneumonia and influenza.

⁵ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹ Total includes unknown ages.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at *http://www.cdc.gov/mmwr/mmwrsubscribe.html*. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41186 Region IV ISSN: 0149-2195